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ABSTRACT 
Synthesis and Opioid-Related Activities of Some 
Cis-and Trans-3-(mono- or dialkylamino)-7-
(methoxy or hydroxy)-1-phenyl-1,2,3,4-
tetrahydronapthalenes 
Cis and trans isomers of 3-(mono- or dialkylamino)-7-
(methoxy or hydroxy)-1-phenyl-1,2,3,4-tetrahydronapthalenes 
were synthesized. Compounds HC-11 (cis) and HT-11 (trans) 
with 3- (dimethylamino) and 7-methoxy substituents and com-
pounds HC-13 and HT-13 with 3-[(cyclopropylmethyl)methyl-
amino] and 7-methoxy substituents were synthesized from 
their corresponding 3~(methylamino) and 7-methoxy deriva-
tives (HC-10 and HT-.~.Q) • HC-10 and· HT-10 were previously 
prepared by reductive amination of the 3-tetralone and 
separated by fractional recrystallization. HC-10 was 
obtained predominantly in a 9:1 ratio. Analysis of proton 
NMR spectral data supports the fact that both the phenyl 
group at C-1 and nitrogen substituents at C-3 of the 
tetralin ring are placed pseudoequatorially in the pre-
ferred conformation for the cis and trans isomers. 
Compounds HC-10-12 and HT-10 and 11 and also HC- and 
HT-~ and 14 were tested for their opioid-related agonist 
and/or mixed agonist-antagonist properties in the guinea 
ii 
-;;===========---=====-=---=-·:-=-=--=-=--=·-·=--_:-::=------ ------- -- --- --- --
pig ileum (GPI) longitudinal muscle assay as described 
by Kosterlitz. 64 These tests show that compounds HC-10 
and HC-11 have agonist activity approaching that for a 
full agonist but at a higher dose level (approximately 
60 x) that for Normorphine (NH) ·• Compounds HC-13 and 
HT-10 were of intermediate potency ranging in activity 
-----from l/T0-0-~17TO_O_Ehe- potency-of--NM. - -Their activi-ties __________ --
are classified as those of partial agonist. The 0-
demethylated compounds HC-~, HC-14 and HT-14 were weak 
in potencies as agonist. Compounds HT-11 and HT-13 
were inactive. 
Agonist activity in these compounds resides pre-
dominantly in the cis isomers as revealed by the superior 
potencies of HC-10, HC-11, HC-13 and HC-14 over their 
trans counterparts. This observation is in agreement 
with those reported earlier6 for the nonphenolic con-
geners 2C and 2T. Naloxone (Nx) only partially blocks 
the activity of these compounds, thus the activity seen 
on the GPI may not be totally opioid in nature. Antago-
nism of NJI1 activity by HC-14 and HT-14, with pA2 values 
of 4. 9 and 4. 6 3 respectively, shmvs that these compounds 
possess little mu receptor antagonist activity. 
iii 
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INTRODUCTION 
Considerable research has been directed at discovering 
potent narcotic agents; however, it has not yielded potent 
nonaddicting analgetic agents for use in clinical situa-
tions,1 nor has it yielded potent long-acting narcotic 
'l 
arrta-g-orr:ls_t_s-f-or-us_e_i~rr-opioia·-a.adict:ion~ rehanirit:atYon:~"--------
Research directed toward discovery of new opioid-related 
mixed agonist-antagonists remains a possible source for non-
addicting analgetics. Narcotic antagonists with improved 
pharmacological properties may also be discovered from nev,r 
derivatives having opioid-related structures. 
Research emphasis on opioids has changed over the last 
few years. Drug companies and researchers in general now 
think that nonaddicting analgetics will be found from com-
pounds with selective action on the kappa or possibly the 
delta opioid receptor. Most of the traditional drugs that 
are mixed agonist-antagonist exert their agonist and antago-
nist effects through different opioid receptors (e.g., most 
are kappa agonists and mu antagonists). 3 
* The aminotetralin derivatives are structural analogs 
of morphine and have shown promise in yielding potent nar-
cotic agonist and antagonist activity. That aminotetralin 
* The Chemical Abstracts preferred name for tetralin is 
1,2,3,4-tetrahydronapthalene. In this dissertation the terms 
tetralin and 1,2,3,4-tetrahydronapthalene are used inter-
changeably. 
1 
' R ~ 
H 
/CH3 N . 
""'c H 3 
2 
3 
derivatives are capable of producing analgetic activity is 
evidenced by the research of Martin and coworkers.4,5 The 
most interesting of the compounds prepared by Martin's group 
have been the 1-phenyl-substituted derivatives lC and lT. 
Their agonist EDso value~ in the mouse hot plate test are 
0.058 and 0.052 mmol/kg (morphine = 0.049 mmol/kg) respec-
tively. 
In a recent report the design, synthesis and opioid-
related activity of aminotetralins having structure 2 were 
described by Fries and Bertelli.6 Of the compounds prepared 
in the course of this research, structures 2C and 2T have 
proven to be the most active. These isomers (2C and 2T) 
showed agonist EDso values in the mouse hot plate of 6.3 and 
9.1 mg/kg (morphine=l.2 mg/kg) respectively~ Narcotic 
antagonist activity assessed by reversal of an EDso dose of 
morphine when tested subcutaneously in mice by the tail flick 
procedure was reported to be 54% at 10 mg/kg for 2T and 75% 
at 1 mg/kg for 2C. The narcotic antagonist activity of 2C 
and 2T is most interesting since the compounds lack two of 
the structural requirements often cited as necessary for 
potent activity. The lacking features are the phenolic 
hydroxyl and the quaternary substituted carbon adjacent to 
the aromatic ring. 
As part of the continuing investigation of these 
selected aminotetralin analogs, this dissertation describes 
the design, synthesis, stereochemical analysis and opioid-
Target Compounds 
(±)-He-
(±)-He-
(±) -HC-
(±)-He-
(±)-He-
Figure I. 
and HT-l.Q. Hel: Rl 
and HT-11 Hel: Rl 
and HT-12 HBr: Rl 
·and HT-13 Hel: Rl 
and HT-14 EBr: R1 
= H,R2 = 
= CH 3 , R2 
= CH 3 , R2 
=-v 
=~ 
R 
\
' CH3 
'}4/ 
-H 
OeH 3 
= OeH 3 
= OH 
R2 = OCH 3 
R2 = OH 
Novel derivatives of 3-amino-1-pheny1-1, 
2,3,4-tetrahydronaptha1ene. 
4 
related activity of the cis and trans isomers of 10, 11, 
and 13. The 0-demethylated products of 11 and 13 also are 
reported. In this dissertation, the prefixes HC and HT 
are used to designate cis and trans isomers respectively. 
There are several structure-activity relationships 
5 
(SAR) which are important in the design of these compounds. 
Firs~ the addition of a phenolic hydroxyl to these isomers 
~---------~--~ ---~ - ----~--- ~-~--------------
should greatly enhance both their agonist and antagonist 
activities. Secondly, the substitution of a cyclopropyl-
methyl or other allylic-type group onto the nitrogen gen-
erally imparts narcotic antagonist activity in rigid struc-
tured op.ioids (e.g., morphine, morphinan and benzomorphan 
derivatives) 2 while like substitution results in agonists 
or inactive compounds in the non-rigid structured opioids 
(e.g., meperidine and methadone derivatives) . 1 ' 2 Similar 
substitutions in the isomers reported in this dissertation 
could be expected to produce narcotic antagonists, or mixed 
agonist-antagonists. 6 Thirdly, the phenyl substituent on 
C-1 may be favorable for affinity to one or more of the 
6 7 
opioid receptor subtypes. ' 
It is desirable to investigate the stereo-chemical 
features of analgetics since it has repeatedly been demon-
strated that stereoisomers of a single structure will 
11 . h . . . d t. . t 8 , 9 genera y vary ~n t e~r op~o~ ac ~v~ y. The amino-
tetralins possess a flexible backbone when compared to the 
rigidly structured morphine molecule. The flexibility of 
6 
! ,, n-.;) N~ 
Structure 2: R = H, OH, OCH 3 
Structure 2C Structure 2T 
7 
the tetralin ring allows these compounds to exist in several 
conformations which might interact with opioid receptors by 
different modes than those which occur with the classical 
rigidly structured compounds. If such additional binding 
modes do occur, one might expect the compounds to show a 
selectivity for the opioid receptor subtypes which is not 
achieved with known compounds. 
LITERATURE SURVEY 
The original three-center receptor proposal of Beckett 
and easy applied to what was then known about the conforma-
tions of the rigid morphine-like, phenylpiperidine, and 
diarylpropylamine analgetics.lO It was postulated that 
ce~~"ta-i-n-s--te-Fee e-h-e-m-i-e-a-1-a-n-d--p-h-y s-i cu ch em-i-c-a--1-p-r-ope-r-t-i-e-s---were----
strategic for morphine-like analgetic compounds to fit a 
proposed receptor site (Figure II). 
In reviewing early SAR it was concluded that potent 
analgetic compounds require four critical structural fea-
tures: (1) a tertiary substituted amine in which the sub-
stituents on the nitrog~n may vary widely, (2) a phenyl 
group or a group isosteric with phenyl connected to, (3) a 
quaternary carbon, and (4) a 2-carbon chain separating the 
tertiary nitrogen and the phenyl group.ll These minimum 
requirements had been deduced by noting the pharmacological 
actions of the remaining partial structures when portions 
of the morphine molecule were empirically removed. Compounds 
that fit this SAR pattern would fit the Beckett and easy 
receptor model. Although a number of potent analgetics not 
possessing all of these structural features have been 
reported, and the validity of these generalizations may now 
be questioned, they remain useful in designing new analgetic 
compounds. 
8 
I 11...-m!lLil:l' ~~lli•IIU I ---'--'--'-"lilll:.='-l.'-' 'C:"'"-' .w.J.--'----'-----~-----.... -
Opioid Receptor: 
Beckett and Casy Model 
X 
I I 
I 
I 
4 ... Pl11.enolic 
Anionic 
Site 
Cavity 
B . I d" IJn. 1ng 
I 
Su:_rface 
Figure II. Original model for the opioid rec~ptor. 
(Ref. 10) . \0 
I 
II 
A dual or multiple aryl binding site hypothesis 
(Pigure III) was proposed by Portoghese to explain the 
activities of a number of opioids that did not fit the 
Beckett and Casy model. 12 He postulated that the binding 
10 
of different narcotic analgetics with opioid receptors may, 
in many cases, involve differing modes rather than a single 
type of drug-receptor interaction. These interactions may 
-------------~--~---~~-------- --~--~ --~~-----~--~-~-----
or may not be on the same site of the receptor. A key 
example which can be used to illustrate this postulate is 
the fact that N-allylnormeperidine _12, unlike nalorphine ]_£, 
which behaves as a morphine antagonist13 but is virtually 
inactive as an agonist in mice or rats, is not an antagonist 
and possesses activity comparable to meperidine. This sug-
gested that the N-substituted derivatives of morphine are 
perhaps complexing with analgetic receptors by modes which 
were dissimilar from those seen for N-substituted meperi-
dines. The possibility of induced fit as a factor contrib-
uting to receptor binding of diverse analgetics was also 
. d 14 recognJ.ze . 
The concept of t-vm different binding modes has been 
15 further modified by Portoghese by suggesting that these 
two different binding modes indicate the presence of compli-
mentary lipophilic binding subsi tes designated (!_} and· (P}. 
The first subsite, which is typified by morphine binding, 
involves occupation of the subsite (T) which interacts with 
the tyrosine (Tyr) aromatic ring of the enkephalins and 
11 
;--~-1--~0_9., ; ~-----
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Figure III. Orientations that t\vO different opioid 
prototypes might adopt relative to one 
another at the receptor. (Ref. 12). 
Structure 15 
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endorphins. The second, which is exemplified by prodine 
binding, involves the interaction of the phenyl group with 
the subsite (P) which also interacts with the aromatic 
residue of phenylalanine (Phe) in the enkephalins. Each of 
the binding modes possesses a common receptor area which 
contains an anionic site. A receptor model consistent with 
these findings is presented in Figure IV. It is also con-
-------
ceivable that the structural requirements for narcotic 
antagonism are related to the binding of the antagonist 
molecule at the (T) subsite of the opioid receptor. The 
phenolic group of morphine contributes to the binding by 
hydrogen bonding with a proton acceptor at the (T) subsite. 
The fact that a phenolic hydroxyl appears to be an absolute 
requirement for potent narcotic antagonist activity is also 
consistent with this view. Furthermore, a number of 
structure-activity studies16 suggest that the (P) subsite 
is more hydrophobic than the (T) subsite and that there is 
an additional hydrophobic area adjacent to the (P) subsite. 
The aminotetralins, which are the objective of this 
research, have structure-activitiy features which are gen-
erally associated with mixed opioid agonist-antagonist 
activity. In the context of the model presented by Porto-
15 ghese, the aminotetralins are A, B ring analogues of 
morphine and hence would be expected to interact similarly 
with the subsite (T). The phenolic hydroxyl present on 
congeners HC- and HT-12 and 14 is expected to contribute 
A 
Figure IV. 
····=··-------------------
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Opioid Mu Receptor Mod~l 
(Phil Portoghese) 
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I 
A schematic illustration of the interaction of erikephalins 
or endorphins (panel A), morphine (panel B), and 
1
prodine· 
(panel C) with opioid receptor subsites (T and P): which 
recognize the aromatic residues of Tyrl and Phe4 /of the 
opioid peptides. The anionic site A is ion pair~d with 
the protonated nitrogen of the opioids in all th~ee cases. 
Group G located on subsite T represents a hydrog~n-bonding 
acceptor dipole. (Ref. 15). f 
I 
!lll~m:IJillnfmlllll!llll ru 
.1. 11 : J.:.I:ITJit:unn.v:mrnr:I:J::n::rm:mrmr .1 •• 11. ..H .. I.l .,Ji 
~ 
~ 
l' "'ili'T]" ·, lniT1T1~11T'T1TT I''IIITm-,rt-·r.n"'llrT<l'ml1'11'l:'ltiTrtTl W 1•:· 'c' rw- '' II 1 ~, 
I 
I 
i 
favorably to the potency of these compounds compared to 
those with features on structures 2C and 2T. They have 
structural resemblance to the mixed agonist-antagonist 
cyclazocine 17 which possesses some 40x the analgetic 
activity of morphine in man. 8 Inclusion of the 1-phenyl 
substituent in the aminotetralin structure could be sug-
15 
gested to correspond to binding to an additional hydrophobic 
--- ---- ------ -------- --------- ---
area adjacent to the (P) subsite. 16 - 18 Evidence that the 
ethylenic bridge is not necessary for activity is provided 
by the aminotet.ralins (18;) prepared by Martin and co-workers. 4 ' 5 
Continuing further in the context of this model, it may be 
proposed that congeners of aminotetralins in the present 
series such as the N-cyclopropylmethyl derivatives HC- and 
HT-13 and !! might show relatively high potency as mixed 
agonist-antagonist due to their simultaneous occupation of 
both the (T) subsite and the second hydrophobic area men-
tioned above in a fashion analogous to the highly potent 
. . d . . 19 d h ~ h. 19 71 h t. or1pav1ne er1vat1ve an t e enaorp 1ns. ft sc ema 1c 
illustration of this interaction is shown in Figure V. 
Molecular superimposability patterns have been used 
to predict configurational relationships and biological 
activity between compounds. This has been a useful method 
for the design of new drug candidates. With the aid of these 
patterns, it was suggested that naloxone-like antagonism 
will be seen in N-allyl-4-phenylpeperidine prototypes that 
interact with the receptor in a conformation in which the 
;=========------~-------
Opioid Mu Receptor Model 
A 
Figure V: A schematic illustration of the inter-
action of 3-[(cyclopropylmethyl)methyl-· 
amino]-7-hydroxy-1,2,3,4-tetrahycro-
napthalene with opioid receptor subsite 
(T) and the additional lipophilic binding 
site proposed in Ref. 16. The anionic 
site is A. 
16 
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4-phenyl is oriented axially but will not be seen in proto-
types that have the 4-phenyl group in an equatorial posi-
. 20 h' tlon. · Morp lne and structurally related phenols interact 
with their receptor in a conformation that has the aromatic 
group oriented axially. Continuing further in the context 
of these patterns, it may be noted that composite structures 
of the (+)- and (-)..:5 ... ph:enylbenzomorphans, superi_Ill_PC>_l:;~<!_<:>~ 
morphine in Figure VI and indicated as A and B respectively, 
provide a structural link between morphine and meperidine. 
It is observed that the benzomorphan enantiomers are closely 
related in their superimposability upon morphine yet they 
7 21 differ 20-fold in potency. ' In addition to the simple 
differences between these (circles), the angle between the 
m-hydroxyphenyl ring and the piperidine ring is different 
by about 60 degrees. The (+)-isomer, 'l.'lhich is more per-
fectly superimposable on morphine, does not suppress with-
drawal symptoms in morphine-dependent monkeys; it precipi-
tates withdrawal. This type of agonist-antagonist action 
appears to be related, among other things, to the disposition 
or orientation of the C-9 methyl groups and the piperidine 
rings and also the absolute configuration of the C-5 carbon. 
The aminotetralins in this series HC and HT (10-14) 
are more flexible or are more conformationally mobile than 
these 5-:-phenylbenzomorphans or, for that matter, morphine. 
Consequently, they might have conformations which are highly 
superimposable on the opioid receptor elements. The 
--b=H ____ -- --- --- -------
A: Composite of a(+)-5-phenylbenzomorphan superimposed 
onto morphine. 
\ C--H 
.. 
. OH 
B: Composite of a(-)-5-phenylbenzomorphan superimposed 
onto morphine. 
Figure VI: Composites of 5-phenylbenzomorphan super-
imposed onto morphine. Nonoverlapping 
portions of morphine are shown as dotted 
lines. 
19 
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disposition and absolute configuration of the C-1 carbon of 
the aminotetralins which correspond to C-5 of the benzo-
morphans and the absence of C-2 substitutents which corres-
pond to C-9 of the benzomorphans may translate into an 
improved alignment of the drug molecule with the receptor 
components. If such an improved receptor fit occurs, it 
may be beneficial to the overall pharmacological properties 
---g--------------------------- --- ---
of the compounds. These patterns are depicted for cis- and 
trans-N 1 N :...dimethylaminotetralins in Figures VII and VIII 
showing their relative orientation to morphine. The cis-
isomer as drawn is more superimposable on the morphine 
molecule~ In the trans isomer the N,N-dimethyl substituent 
is anti to the 1-phenyl group and therefore expected to 
end up on the opposite side of the receptor as opposed to 
interaction on the same face as seen for the cis isomer. 
A problem with the representation shown in Figures VI and 
VII is that it assumes a pseudoaxial conformation for the 
aminotetralins. These types of interactions are considered 
only in the event that induced fit of the molecule onto the 
_receptor is possible. In order for this process to take 
place, free energy released from initial ligand-receptor 
interaction has to be sufficient to bring about a reorien-
tation of the molecule onto the receptor surface. The 
possibility of induced fit as a factor in the binding of 
14 
analgetics has been cited by Portoghese. 
Figure VII: 
21 
Q::;~H----
Possible relative orientations of morphine 
and cis-7-hydroxy-3-(dimethylamino)-1-
phenyl-1,2,3,4-tetrahydronapthalene [HC-12]. 
Morphine nucleus is dotted in to show rela-
tive orientations of these two compounds. 
lJlo-H 
Figure V!II: Possible relative orientations of morphine 
and trans-7-hydroxy-3-(dimethyl~~ino)-1-
phenyl-1,2,3,4-tetrabydronapthalene 
[ET-12]. N,N-Dimethyl substituent is 
antito the 4-phenyl substituent. Horphine 
nucleus is dotted in to show relative 
orientations of these two compounds. 
j 
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Bridged aminotetralins that showed analgetic activities 
in rats ranging from 1/50 to 20 times that of morphine were 
reported by Freed et. al. 22 - 24 Some aminotetralins 
reported by this group showed antagonist activity ranging 
from 1/100 to 1/2 that of nalorphine in monkeys. These 
are examples of only a fe~.¥ series of compounds which have 
l _______ shown significant narcotic -~!1!-~_9"<?.!1.1__~!-~-~ _'-1~-t:._:i._v:_i_-t:Y_~"t"l_il-_e_ _ _______ _ 
lacking the N-allyl-type substituent. Takeda and co-
25 
workers have also reported other bridged aminotetralins 
with analgetic potency in the range of morphine. 
Half chair conformational structures for aminotetralins 
in this series are depicted in Figure IX showing axial and 
equatorial orientation of the N,N-dialkylamino group. NMR 
spectral data indicates that there is a greater preference 
for the equatorial 3-amino orientations 20b and 2lb rather 
than the more morphine-like axial amine conformation 20a 
and 2la where the 1,3-diaxial steric interactionS would be 
more severe. For agonist activity that is reminiscent of 
morphine among aminotetralins in this series, the conforma-
tion shown as 2la might be assumed to be interacting with 
the receptor. In this N-axially oriented half chair 
conformation of the tetralin system, the molecules would 
be capable of fitting Beckett's proposed receptor without 
using the cavity postulated to exist between an anionic 
site and a flat surface of an aromatic ring. The essenti-
ality of an axial orientation of the amino function, however, 
:: 
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Aminotetralin Analogues 
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Figure IX: Half chair conformational structures for cis-
and trans-3-(dialkylamino)-7-hydroxy-1-phenyl-1, 
2,3,4-tetrahydronapthalenes. 
., 
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has been disputed by the identification of analgetic com-
pounds in which the amino group is oriented in a position 
comparable to the equatorial position of the half chair 
tetralin system (Figure IX) . 26 
24 
In the light of reports by Fries 6 and Martin27 and of 
the concept of Portoghese12 that differing modes of binding 
of different narcotic analgetic receptors may occur, 
activity might reside in either conformation of the 2-
aminotetralins. It is also conceivable that the energy 
barrier to interconversion of the two half-chair conforma-
tions (Figure IX) in the system is not sufficiently large 
to prohibit a drug-receptor interaction from providing the 
force to reorient the amino group into the less stable 
axial conformation should it be required, perhaps less so 
in the case of N-cyclopropylmethyl substituent, in which 
1,3 diaxial interactions are expected to be more severe. 
The conformation with the N-cyclopropylmethyl substituent 
oriented equitorially may therefore be especially favored. 
The aminotetralins, because of their flexibility, are 
capable of existing in a number of conformations. Thus, 
one would expect the aminotetralins to present a variety of 
conformations which may interact with opioid receptors as 
opposed to the more rigidly structured morphine. In other 
words, the additional binding modes that are possible with 
these compounds might allow for selectivity in their inter-
actions with opioid receptor subtypes, which is not possible 
25 
with known compounds. This view of drug-receptor inter-
action for these aminotetralins provides a basis for ration-
alizing analgetic and antagonist activities, and also a means 
of explaining receptor selectivity which may occur. 
Martin, in an extensive review of opioid receptor 
pharmacology, has postulated a three dimensional model to 
28 depict the kappa opioid receptor. Agonist molecules are 
----
required to have certain key features in order to bind to 
this model. These include a benzene or phenolic ring which 
complements a flat surface (A) on the receptor by forming 
Vander Waals bonds. An anionic site (B') for binding to the 
2-nitrogen group of benzomorphans is also required. This 
site is said to be located approximately lA above and to the 
right of the anionic site (B) for morphine and related 
structures (Figure X). A third site, designated the D-site, 
interacts with the ketonic oxygen on the 8-position of 
ethylketazocine ~ (10 position of the morphine molecule). 
It also interacts with the bulky heads of N-allyl or N-
cyclopropylmethyl substituents. The interaction with the 
D-site for N-allyl or N-cyclopropylmethyl .substituted 
morphine molecules on either mu or kappa receptors causes 
a clockwise rotation of the rest of the molecule in a direc-
tion that moves the cationic nitrogen away from its normal 
binding mu locus or site designated B to a kappa site B'. 
This D-site induced molecular rotation is favorable 
for kappa receptor agonist effects; hoever, at mu receptors 
-i 
!! 
I 
Opioid Receptors: 
Composit Drawing 
(Wm Martin) 
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Figure X. 
10 
-5 
A schematic oblique view of a hypothetic opioid 
receptor (Ref. 28). Alphabetic letters are 
usee to designate reactive sites and x, y and z 
coorainates in Angstrorr.s are presented in 
parenthesis. 
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agonist activity is lost. Since the molecule is still in 
close proximity to the receptor it inhibits the binding of 
mu agonist molecules. This type of mu antagonist activity 
is weaker in nature both in terms of its binding energy 
and ease of reversibility when compared to that seen for 
morphine congeners that possess the 14-0H in addition to 
the N-allyl (naloxone) or N-cyclopropylmethyl (naltrexone) 
[~] which are called pure antagonists on the mu and kappa 
receptors. The presence of the 14-0H group in these con-
geners prevents rotation of nitrogen into the B' site of 
the kappa receptor, but the attraction of the N-allyl or 
N-cyclopropylmethyl group for the D-site places the nitro-
gen in these compounds above both the anionic site for kappa 
and mu receptors. 
The 3-[(N-cyclopropylmethyl)amino]tetrahydronapthalene 
compounds reported in this research, on careful examination, 
can be seen to possess molecular features which may allow 
their interaction at the proposed kappa receptor model and/ 
or mu antagonist model. The presence of phenolic group in 
-
I 
receptor. The N-cyclopropylmethyl substituent in HC- and 
~ 
I 
these molecules allows binding to the flat surface on the 
HT-13-14 could conceivably interact at the D-site on mu 
receptors and as proposed above, cause a rotation of the 
molecule in a direction that places the cationic n'itrogen 
at the B' kappa anionic site. If this mechanism were 
operational, one would see mu antagonist activity. Since 
Structure 22 
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Figure XI. The structures of opioid ligands that bind to 
the hypothetic receptor model in Figure X. 
Reactive sites for substituents are indicated 
with alphabetical letters. 
= 
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there is no hydroxy substituent in these molecules eguiva-
lent to the 14-0H in naloxone, one would not expect them to 
show pure antagonist activity. 
One could also attempt to fit compounds MC-13 or 
14 in their preferred conformations (i.e., structure 2lb, 
Figure IX) to Martin's model for the kappa receptor. As 
drawn in Figure IX, 2lb has the 3-N in a pseudo-eauatorial 
--- - ~ ~--------------------- ---- --------
position. Molecular modeling reveals that the cationic 
nitrogen in 2lb could readily bind to the B' binding site 
in Martin's kappa receptor model. The "better fit" of 2lb 
to the kappa model occurs because the B' site is postulated 
to be higher topographically in kappa receptors than the 
B site in the mu receptor. Conversely, the nitrogen sub-
stituent in morphine and related structures is axially 
oriented and better suited to bind the B anionic site. The 
flexible nature of HC-13 and HC-14 (Figure XI) compared to 
the more rigidly structured benzomorphan or morphine \tlOuld 
allow for juxtapositioning of groups or substituents neces-
sary for additional binding in such a manner that it will 
afford a proper fit. The 1-phenyl substituent in this 
regard is seen as interacting at a large binding site 
designated H and cited by Bentley and Lewis 29 as binding 
site for a large moiety substituted on 7-position of thebain 
derivatives. With such proper fit at a receptor, selec-
tivity can be achieved. 
30 
Very recently, Portoghese and Takemori, 30 using binding 
studies done with beta-funaltrexamine (beta-FNA) 24 and 
its N-methyl analogue, beta-fuoxymorphamine (beta-FOA) 25, 
have concluded that there might be separate recognition 
sites for opioid agonist:·and~ant~goni~t~activity. Though 
each of these ligands differs. only in the nature of the 
N-substituents, only beta-FNA irreversibly blocks the 
agonist action of mu agonists. It interacts covalently 
and alkylates a site that is uniquely coupled to the mu 
receptor. Beta-FOA, on the other hand, is a reversibly 
acting mu agonist with no detectable irreversible activity. 
Naloxone and naltrexone thereby exert their antagonistic 
effect by interacting with a neighboring regulatory site 
designated rho ~) which is allosterically coupled to the 
mu receptor. A model consistent with the data accumulated 
from these studies is illustrated schematically in Fig-
ure XII. 
Separate agonist and antagonist sites have been postu-
lated from in vivo data. 31 Also an allosteric model for 
the interconversion of agonist and antagoni~t binding 
conformations of the opioid receptor have been proposed. 32 
Attempts to isolate the opioid receptor have met with 
only limited success. Experiments with sulfhydryl reagents 
and proteolytic enzymes have revealed that the receptor is 
probably composed of protein associated with membrane 
lipids. The evidence for a lipid component is reinforced 
31 
R 
Structure 24: B-FNA, ?.-CE2CH(CH 2 ) 2 
Structure 25: B-FOA, R-CH 3 
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Figure XII. A model of the interaction of rnu agonist ( 0 ) 
and antagonist (•) with the mu opioid receptor 
and a neighboring regulatory site rho (p ) . 
An agonist at low concentration binds selec-
tively to the ~u receptor (b) and at higher 
concentrations to the p regulatory site (c). 
The latter interaction triggers a vectorial 
decrease in the affinity of the rnu receptor 
(illustrated as~). The selective inter-
action of an antagonist at the p site induces 
a vectorial loss of affinity of the rnu receptor. 
(Ref. 3 0) • 
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Figure XIII. Cerebroside as a model for the opioid 
receptor. (Ref. 35). Possible stero-
selective binding of an aminotetralin is 
depicted. 
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by the ability of the cerebroside sulfate and phosphatidyl 
serine to stereospecifically bind opioids. The binding 
of opioids to cerebroside sulfate in particular produces a 
good correlation with in vivo potency, 33 a finding that 
33 34 . has led Loh and others ' to propose that cerebroslde 
sulfate can fulfill many of the requirements dictated by 
the medicinal model of the opioid receptor (Figure XIII). 
The biochemical role of the enkephalins and opioids 
34 
is not completely understood, but both are "indirect .. inhibi-
tors of adenylate cyclase, the enzyme that catalyzes the 
conversion of 5'-adenosine triphosphate (ATP) to 3' ,5'-
adenosine monophosphate (C'AMP) . 35 The opioid receptor 
subtypes that these bind to are supposedly coupled to 
cyclase. Occupation of the receptor by opioids is trans-
lated into a decrease in cyclase activity, causing a lowering 
of C'AMP levels and resulting in analgesia. C'AMP and C'GMP 
are normally physiologic antagonists. Analgesia has been 
effected by C'GMP. 35 
On the basis of pharmacological actions in man and 
experimental animals, Martin and co-workers 36 , 37 have 
postulated the existence of three subspecies of opioid 
receptors, designated mu, kappa, and sigma. The prototype 
agonists for these receptors have been initially assigned 
as morphine (mu) , ketocyclazocine (kappa) , and N-allyl-
normetazocine [SKF-10, 04 7] (sigma) • Naloxone is a proto-
type mu antagonist. A more recently reported kappa 
-
I 
~ 
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. . T 2 38 antagon1st 1s ENA 6. It was reported that TENA was 
approximately 27 times more effective in antagonizing the 
kappa agonist U-50,488H relative to mu agonist morphine, 
and was five times more effective against ethylketocycla-
zocine (EKC) relative to morphine. For the delta receptor 
in the mouse vas deferens the most selective antagonist 
reported is ICI-154,129. 39 
Many mixed agonist/antagonists compete with morphine 
at the mu receptor, but do not themselves have agonist 
actions or may be parti~l agonists at this receptor. 3 
Their agonist activity is expressed through the other two 
receptors, the kappa receptor mediating their analgetic 
actions and nalorphine-like dependence, and the sigma 
receptor mediating their psychotomimetic effects. 37 Other 
mixed agonist/antagonists are partial agonist at the mu 
receptor where they elicit enough agonist activity to 
produce a clinically significant degree of analgesia but 
not enough agonist activity to produce significant dependence 
t . . 28 or OXlClty. 
At the same time that evidence of multiple opioid recep-
tors was being accumulated by classical behavioral techniques, 
in vitro studies using receptor binding assays and the guinea 
pig ileum and mouse vas deferens preparations independently 
pointed to a similar conclusion. Hutchinson et a1. 40 
studied a series of benzomorphans using these assays and 
found that an enhanced guinea pig ileum/mouse vas deferens 
potency ratio coupled with poor reversal of activity by 
;(================================~~~~~~==-------------------- --------- -----------~-- ------
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naloxone is predictive of interactions at the kappa recep-
tor, and hence of low morphine-like dependence liability. 
This conclusion is consistent with that predicted by 
. 36 
Martin's in vivo work. . 
Biochemical studies in rat brain have confirmed that 
37 
sigma opioids interact, as Martin had postulated, with mul-
tiple classes of bpioid receptors and that one of these 
classes is inaccessible to nonsigma opioids. 41 Specific 
[ 3H]-phencyclidine (PCP) binding studies were carried out 
in homogenates prepared from different regions of post mortem 
human brains derived from subjects free of any neurological 
disease. In these studies, various sigma opioids displaced 
specifically bound [3H] PCP binding in a rank order similar 
h . b . 42 to t at seen ~n rat ra~n. 
The distribution of mu opioid receptors in monkey 
cerebral cortex has been determined by autoradiographic 
visualization of [ 3H]-naloxone binding. In the rat the 
so-called mu receptor sites appear to mediate the morphine-
induced release of prolactin, but not growth hormone. Evi-
dence supporting the concept that mu receptor mediates 
antinociceptive activity have continued to accurnulate. 45 , 46 
One of the several mu receptor-selective ligands that has 
been reported is the octapeptide somatostatin analog, 
SMS-201,995, which is mu selective in vitro and has antago-
nist properties in vivo (vs. morphine, mouse tail flick). 46 
The existence of kappa receptots is now well estab-
lished by: (1) the selectivity of dyporphins and alpha-
~-------- ---
----- --=- --~ _-:__-_ --- __ - -
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38 
. 47 48 
neoendorphins for receptors in isolated tlssues; ' 
(2) the remaining kappa binding sites in guinea pig brain 
and spinal cord after suppression of the mu and delta 
binding sites with highly selective mu and delta ago-
nists;49,50 (3) the unique distribution of kappa binding 
sites in the cerebral cortex in guinea pig brain utilizing 
autoradiographical visualization; 51 (4) kappa specific 
52 
receptors on human placental membranes and rabbit vas 
deferens; 48 and (5) the discovery of several new kappa 
selective compounds. 53- 55 Kappa agonists have been reported 
as having diuretic activity in the rat; 56 their analgetic 
activity is mainly at the spinal leve1. 57 The benzodiaze-
pine analog, triflouadom, ~, which is devoid of benzo-
diazepine-type activity, has been reported as an orally 
effective kappa opioid analgetic, produces no respiratory 
depression in rats, was not self-administered by rhesus 
53 
monkeys, and did not elicit opioid withdrawal symptoms. 
It is interesting to note the structural similarity between 
27 and the aminotetralins reported in this series. Simi-
larity is noted in terms of A,B-ring relationship, position-
ing of the phenyl group and also the 2-acyloaminomethyl side 
chain relative to the aminotetralins reported in this series. 
Another recently discovered kappa-selective agonist 
t d . 1 . 50 488 53- 55 d' 1 1 t' repor e prevlous y lS U- , H. It lsp ays ana ge lC 
actions in a variety of antinociceptive assays in rodents, 
and causes opioid receptor mediated sedation, diuresis and 
-- _____ - _____ ...:::;. 
- ___ .....::: 
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corticosteroid elevation. U-50,488H does not produce 
physical dependence, but produces tolerance upon chronic 
administration. Receptor binding, cross tolerance, and 
behavioral models distinguish its effects from those of 
morphine, a mu agonist. 
The irreversible mu-antagonist beta-FNA has been 
reported to block the activity of normorphine and leu-
enkephalin, but not of dynorphin or ethylketocyclazocine, 
in the guinea pig ileum, which further suggests that DYN 
58 
acts predominantly at kappa receptors. A guinea pig 
brain membrane preparation containing only kappa-receptor 
40 
sites can be obtained by treating membranes with beta-
chlornaltrexamine (beta~CNA) in the presence of dynorphin. 59 
The novel compound N,N-bisallyl-Tyr-Gly-Gly-4(CH2S)-
Phe-Leu-OH (ICI-154,129) was shown to be a selective delta-
receptor antagonist in the mouse vas deferens. 39 Further-
more, ICI-154,129 antagonized the slowing of the etorphine 
induced head turn in rats 60 which appears to be an in vivo 
d 1 f d 1 t . t. 60' 61 roo e o e ta-receptor ac lVa lon. The mu antagonist 
beta-FNA, at doses that antagonized morphine analgesia, 
failed to alter shock, whereas the delta-antagonist ICI-
154,129 was shown to reverse shock at doses that failed to 
block morphine analgesia. 62 Therefore, selective delta-
antagonists may have therapeutic value in reversing circu-
latory shock without altering the analgetic actions of 
endogenous or exogenous opioids. 
-------'---~~--~------------------
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Lord et a1. 63 found that Met- and Leu-enkephalin, but 
not beta-endorphin, demonstrate an enhanced activity on the 
mouse vas deferens compared to its guinea pig ileum activ-
ity. This led them to suggest that, whereas beta-endorphin 
has a large morphine-like (mu) component of action, the 
enkephalins interact heavily at a new group of distinct 
receptors which they termed delta receptors. In terms of 
tissue selectivity, it is now known that the guinea pig. 
ileum myenteric plexus-longitudinal muscle preparation 
sensitively detects mu pharmacological activity, 64 that the 
mouse vas deferens preparation sensitively detects delta 
opioid pharmacological activity, 65 and that the rabbit vas 
deferens preparation sensitively detects kappa pharmacologi-
cal activity. 66 An aminotetralin could conceivably be 
selective for one of those receptors. 
The value of a model for research into the mode of 
action of morphine-like drugs at a cellular and molecular 
level can be assessed from its ability to predict the 
potencies of these compounds. Because many of these drugs 
have agonist and antagonist properties, a prediction of the 
relative agonist and antagonist activities is required. In 
the whole animal or in man, the agonist activity becomes 
evident as analgesia, depression of respiration, euphoria, 
and other pharmacological manifestations observed after 
administration. An examination of the action of morphine on 
neuronal junctions outside the central nervous system has 
--
--- -- ---- . -----
---------
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shown that it depresses impulse transmission at certain 
junctions of the autonomic nervous system; these sites are 
exceptions rather than the rule and they are not character-
istic of either species or organ or tissue. 
Depression of impulse transmission in the electrically 
stimulated guinea pig ileum is due to a reduction in acetyl-
choline release. 67 In the rabbit ileum, morphine does not 
reduce transmitter release. 68 Two morphine-sensitive 
adrenergic junctions have been found, namely in the nicti-
tating membrane of the cat69 , 70 and in the vas deferens 
f th b t t . th t . . bb . 71 o e mouse u no 1n e ra , gu1nea p1g or ra 1t. 
The adrenergic junctions in the sinoauricular node of the 
72 d h . cat an t e myenter1c plexus of the guinea pig are not 
affected by morphine. 73 Narcotic drugs can be grouped as 
compounds with mainly agonist action, as compounds with 
mainly antagonist action, and as compounds with dual agonist 
and antagonist actions. Agonist activities are measured by 
the depression of the contraction of the longitudinal 
muscle evoked by coaxial electrical stimulation, the rela-
tive potencies are compared to the available clinical data 
on analgesia in man. 74 - 76 
Antagonist activities are measured in the whole animal 
or man by the reversal of the action of morphine-like drugs 
or by the induction of withdrawal when there is chronic 
dependence on morphine-like drugs. At present the most 
promising models are first, the coaxially stimulated ileum 
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of the guinea pig, second, the electrically stimulated 
preparation of the mouse vas deferens, and third, the 
stereospecific binding capacity of brain homogenates. Mu 
antagonist activities of new compounds are estimated by the 
antagonist effects on the depression of the logitudinal 
muscle contraction in the guinea pig ileum by standard 
concentrations of morphine or normorphine; the antagonist 
potencies are compared to the potencies of the compounds 
to cause withdrawal symptoms in the morphine-dependent 
monkey. 77 , 78 Naloxone-HCl is used as a standard for the 
mu antagonist effects. The kappa antagonistic effects are 
assayed by the ability of test agents to reverse the action 
of selective kappa agonist ethylketazocine and bremazocine. 
Naloxone and WIN43632 (selective kappa antagonist) are used 
as standard antagonists in the assay. 
. . 1 79 - 81 h h h . b t. f Takemor1 et a . ave s own t at pre1ncu a 10n o 
an ileum strip with beta-FNA [5 x 10-9M] for 45 min and 
washing the tissue 20 times with 10 mL portions of buffer, 
results in alkylation of all mu receptors but leaves the 
kappa receptors free. The alkylation of the mu receptors 
is an antagonistic effect (no response to normorphine, 
dihydromorphine, methadone, etc.) while the kappa receptors 
are left unalkylated and thus free to respond to kappa-
agonists and antagonists. Treatment of ileum strips with 
beta-FNA will thus allow one to separate kappa agonistic 
effects from mixed mu and kappa agonistic effects and 
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inhibition constant for the kappa agonistic effect can be 
calculated. 
Similar conclusions have been reached by other inves-
tl·gators.49'50 At 1 'f' k · t ld · ru y spec1 1c appa agon1s wou g1ve 
the same inhibition constant for a test antagonist whether 
or not the ileum strips are beta-FNA pretreated. 
House vas deferens (HVD) contains delta and mu recep-
82 . 
tors predominantly. Wuster, Schulz and Herz reported that 
MVD from mice made tolerant to a mu agonist (sufentanyl) 
will display a response only to delta agonist while MVD 
from mice made tolerant to delta agonist (D-Ala-D-Leu-
enkephalin) will respond· only to mu agents. 
Antagonist activity is reported as Ke values (antago-
nist concentration which required a doubling of the agonist 
concentration to give the same pharmacological response 
obtained in the absence of an antagonist) . Thus compounds 
with selective mu antagonistic effects would display lower 
Ke values in reversing selective mu agonists in in vitro 
preparations containing mu opioid receptors than when tested 
against agonists in the same in vitro preparation containing 
other than mu agonist selectivity. This is demonstrated 
by the fact that in the GPI assay the Ke for naloxone HCl is 
lower when tested against mu agonist·normorphine than when 
it is tested against the kappa agonist ethylketazocine. 
Selective delta antagonism would be apparent by low 
Ke to block a selective delta agonist (D-Ala-D-Leu-enkephalin 
or Tyr-D-Ser-Gly-Phe-LEU-Thr) in the HVD assay compared to 
the Ke to reverse normorphine in this preparation. Each 
Ke is determined by the single dose method. 
45 
EXPERIMENTAL SECTION 
Melting points were determined in open glass capil-
laries using a Thomas-Hoover Unimelt apparatus and are 
uncorrected. , IR (infrared) spectra were recorded with a 
Perkin-Elmer 282B instrument. 1H NMR (nuclear magnetic 
resonance) spectra were recorded on Varian XL-200 (200 HHZ), 
Bruker WM 300 (300 MHZ) or Nicolet (360 MHZ) spectrometers 
and are reported in ppm values. 1 Some H NMR spectra had 
Me 4si as internal reference. NMR multiplicities are reported 
by using the following abbreviations: s, singlet; d, doublet; 
t, triplet; q, quartet; m, multiplet; dd, double doublet; 
br, broadened. All solvents were ACS reagent grade and 
were used without further purification unless otherwise 
stated. Abbreviations used are: THF (tetrahydrofuran), 
DMSO (dimethylsulfoxide), c 6H6 (benzene), EtOH (ethanol) 
and MeOH (methanol) . 
Column chromatography was performed with 230-400 mesh 
EM silica gel. Separations were achieved with a 50-cm glass 
column (40 mm i.d.) that had a 2000 mL reservoir and was 
packed with a slurry of silica gel in either CH 2c1 2 or the 
less polar solvent when a combination of solvents were used 
for elution. The flow rate was generally adjusted to obtain 
approximately 0.5-1.0 mL/min of eluted solution. Thin layer 
chromatography (TLC) was carried out on E. Merck 0.25 mm 
46 
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precoated silica gel glass plates (60F-254) and UV light 
and/or iodine were used as visualizing agents. The follow-
ing solvent systems were used for developing as specified 
for both column and thin layer chromatography: 
2-Propanol (19:1); (B) CH 2cl 2 ; (C) Methanol; and (D) CH 2cl2/ 
Methanol (18:2) + 1% NH 40H. Electron-ionization mass spectra 
(EIMS) were obtained with a Hitachi Perkin-Elmer ID1U-6E 
spectrometer (70 eV). Chemical ionization mass spectra 
(CIMS) were obtained with a V.G. Micromass 707F spectrometer. 
Mass spectra and elemental analysis were performed on sub-
mitted compounds at the section for Analytical Services 
and Instrumentation at NIH, Bethesda, Maryland. 
85 Ethyl 3-(3-Methoxyphenyl)propenoate 3B 
48 
An EtOH solution (443 mL) containing 3-methoxycinnamic 
acid (150 g, 0.84 mol), c 6H6 (1400 mL) and H2so4 (3.5 g) 
was refluxed for 20 h, using a Dean Stark trap for azeo-
tropic removal of water. The mixture vJas concentrated to 
200 mL by slow distillation at 1 atm, cooled and then neu~ 
tralized with 5% NaHco 3 . This mixture was extracted with 
CH2CL 2 , dried (Na 2so4 ), filtered and the solvent removed in 
vacuo to give an oily residue. Distillation at 123-127°C 
(0.1-0.05 mm Hg) [lit. 85 bp 126-127°C (0.1 mm Hg)] afforded 
171.6 g (99%) of ethyl 3-(3-methoxyphenyl)propenoate as a 
-1 
colorless viscous oil: IR (film) 1715, 1640, 1170 em 
1 . 
H NHR 7.73 (lH,d), 7.54-7.01 (4H,m), 6.64 (lH,d), 4.20 
( 2H, q) , 3. 8 0 ( 3H, s) , 1. 2 3 ( 3H, t) . 
49 
Ethyl 3-Phenyl-3-(3-methoxyphenyl)propanoate! 
To a stirred suspension. of copper (I) chloride (2.18 g, 
0.022 mol) in dry ether (120 mL) was added 1.0 .t-1 phenyl-
magnesium bromide in ether (242.3 mL. 0.727 mol) at -15 to 
-20°C in a modified method of Suzuki et a1. 86 The resulting 
suspension was maintained at the above temperature for a 
further 30 min. To this stirred suspension was added 3B 
(75.0 g, 0.364 mol) by drops and the temperature range 
above was maintained for a further 45 min. The mixture 
was allowed to warm to room temperature, stirred for the 
next 10 h, and then slmv-ly poured into 5% HCl (200 mL). 
The layers were separated and the organic phase was washed 
with 5% NaHco 3 (2 x 200 rnL) and dried (Na. 2so4 ). Distilla-
tion at 165-170°C (0.1-0.05 mm Hg) afforded 72.7 g (70%) 
of :ethyl 3-phenyl-3- (3-methoxyphenyl)propanoate (~) as a 
colorless viscous oil which by TLC (Rf{B) 0.62) :showed_it 
to be one spot. IR (film) 3085, 3030, 1732, 1250 cm-1 ; 
1H NMR (DMSO) 7.01-6.70 (9H,m), 4.4 (lH,t), 3.94 (2H,q), 
3. 70 (3H,s), 3.35 (H..,O,s), 3.1 (2H,d). 
£. 
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4-(3-Methoxyphenyl)-4-phenyl-1-sulfinylmethyl-2-
butanone 5 
A 50% oil dispersion (16.2 g) of NaH (8.10 g, 0.34 mol) 
was washed twice with hexane under a stream of nitrogen. 
DMSO (216 mL) was added and the resulting mixture was 
stirred under nitrogen for 6 h. To the cooled solution 
(10°C) was added dropwise with stirring! (48.0 g, 0.17 mol) 
in 150 mL of THF (purified by distillation over Na metal). 
After addition was completed, the reaction mixture was stirred 
at room temperature for 5 h. It was then poured into an 
ice-H2o mixture, the pH was brought to 3 with dilute HCl, 
and this mixture was extracted ''lith of CHC1 3 ( 2 x 400 mL). 
The combined extracts were washed with H2o and dried (MgS0 4 ). 
Filtration and removal of the solvent in vacuo gave 51.5 g 
(96%) of crude 5. An analytical sample of ~ was obtained 
0 by recrystallization from 95% EtOH; mp 102-103 C; IR (KBr) 
-1 3060, 3030, 2950, 2840, 1710, 1600, 1260, 1045 em . 
(CDC1 3 ) 7.50-'6.76 (9H,m), 4.71 (lH,t), 3.78 (3H,s), 3.70 
(2H,s (, 3.41 (2H,d), 2.39 (3H,s). 
c H 
Percent calculated 68.32 6.38 
Percent Found 68.57 6.60 
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1,2,3,4-Tetrahydro-7-methoxy-4-methylthio-1-phenyl-3-
napthalenone [6A and 6B] 
- -
Compound~ (43.0 g 1 0.14 mol) and trifluoracetic 
anahydride (38.5 mL 1 0.27 mol) were refluxed under nitrogen 
in 500 mL of dry acetonitrile for 1.5 h as described by 
Cannon et a1. 87 The cooled reaction mixture was washed 
with 5% Na 2co3 and volatiles were removed in vacuo to leave 
31 g of an orange-red oil which was utilized in the next 
step without purification. A portion of this mixture was 
chromatographed (A) on silica gel to afford an oil which 
by TLC (Rfs (A) 0.29 and 0.36) showed this to compose of 
two spots. IR (film) 3635 1 3060 1 2960 1 1740 1 1620 1 1590 1 
1490 1 1260 1 700 em. A part of this oil was crystallized 
from EtOH/ethyl acetate (9:1) to yield 6A: mp 127-128°; 
1 H NMR (CDC1 3 ) 7.75 (lH 1 d) 1 7.40-6.60 (8H 1 m) 1 4.51 (lHidd), 
3.21 (lH 1 dd) 1 2.68 (lH 1 dd) and 1.68 (<lH,brs). A second 
crop of solid was obtained by repeated crystallization from 
EtOH to yield 6B: mp 132-134° NMR (CDC1 3 ) 7.63 (1H 1 t) 1 
7.47-6.85 (8H 1 m) 1 5.41 (1H 1 s), 4.62 (1H 1 dd) 1 4.12 (3His) 1 
3.32 (1H 1 dd) 1 2.80 (1H 1 dd) 1 1.85 (lH,br s) 1 CIMS (NH 3 ) 
m/e 239 [M - CH 2:;::S 1 - :cil3 J+,. 
,,__.'ll!,!o!,IIIIIIII+ . .J 
-
........ .. 
·- ·- ·-
... ·-
• • t 
·- ·-
... ·-
.. / .... 
·-t' / 
... ,-
~-.-
~-r...-r ,r .. 
f 
.. 
-J \L __ L 
-.. --
-,--,-- .,- ,-r- ,--,-·t- r- •-~r- r-r-·r-·r· r: --,-,- .-·r-r· -r--r- -r- r-,t-.--.--,--
J ,••~ r 
/ 
~J L ____ "' --
"---;Jc_~L-- .-..--~~· .--.-. . ~I i 1 I I -,..L.y--,--,--,-,.-"T-yr·-i--t-,-.·- y-r-y·-,-~-r-,-,-._,-,.-.-..--,--y-l=""t-,..-,.-,-r--.--.-r-e ):. t. I ,-., • t t 
Figure XIV. N~IR Spectra of 1,2,3,4-tetrahydro-7-methoxy-4-methylthio-1-
phenyl-3-napthaleQone [61\ in CDC1 3 J. 
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phenyl-3-napthalenone, [_§_). : 
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Figure XVI. CIMS of 1,2,3,4-tetrahydro-7-methoxy-4-methylthio-
1-phenyl-3-naptha1enone [6D). 
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Figure XVII. NHR Spectra of 1,2,3,4-tetrahydro-7-methoxy-4-
methylthio-1-phenyl-3-napthalenone (6B in CDC1 3 ). lJ1 lJ1 
1,2,3,4-Tetrahydro-7-methoxy-1-phenyl-3-
napthalenone (~_) 
To a solution of crude£ (22 g, 0.073 mol) in 300 mL 
?HF and 200 mL water, was added aluminum (Al) amalgam 
freshly prepared from 10.0 gAl (dipped into 500 mL of 2% 
56 
aqueou~ HgC1 2 for 15 sec. and washed with EtOH, then ether) 
according to the method of Corey and Chaykovsky. 88 The 
mixture was stirred at 5°C for 10 min. and then maintained 
at 65°C for approximately 17 h. The cooled reaction mix-
ture was diluted with 300 mL of CH 2c1 2 and was filtered 
to then remove the Al(Hg). The filtrate was concentrated 
in vacuo and extracted with aqueous solution saturated with 
NaCl. The aqueous phase was .. reextracted .with CH 2c1 2 (2 x 
100 mL) and the CH 2c1 2 layers combined, dried (Hgso 4), fil-
tered and volatiles removed in vacuo to afford a red 
residue which was crystallized from EtOH to yield 13.6 g 
(73.8%) of~ as white crystals; mp 177-178°C; IR (KBr) 3060, 
-1 1 2950, 1740, 1600, 1490, 1260, 700 em ; H NMR (CDC1 3 ) 
7.70-6.71 (8H,m), 4.53 (lH,t), 3.75 (3H,s), 36.60 (2H,s), 
3.08 (2H,d); CIMS (NH 3 ), m/e 253 (~+~·il~ 
c H 
Percent calculated 80.97 6.40 
Percent Found 81.00 6.44 
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Figure XVIII. NHR spectra of 1,2,3,4-tetrahydro-7-rnethoxy-1-
phenyl-3-napthalenone l! in CDC1 3 ). V1 ........ 
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Figure XIX. IR spectra of 1,2,3,4·-tetrahydro-7-methoxy·-1-
phenyl.-3-napthalenone (9). lJ1 
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Figure XX. CUtS of 1,2,3,4-tetrahydro-7--methoxy-1-pehnyl-
3-naptha1enone (9). 
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1-Phenyl-4-(4-Methoxyphenyl)-3-Buten-2-0ne (8) 
0 To a warm solution (55 C) of 0.038 M aqueous NaOH 
(320 mL, 0.012 mol) and 10 g (0.061 mol) of 4-methoxyphenyl-
acetone (7) was added benzaldehyde (6.67 g, 0.063 mol). 
The mixture was maintained at 68-70°C for the next 2 h and 
then kept at 58°C for a total reaction time of 21 h. Water 
was decanted from the cooled mixture leaving an oily yellow 
cake, which was recrystallized from MeOH and dried in 
vacuo to give 11.2 g (73%) of ~: mp 83-84°; IR (KBr) 3070, 
3010, 2930, 1655, 1250, 750 cm-li 1H NMR (CDC1 3 ) 7.68 (lH,d), 
7.60-6.91 (9H,m), 6.80 (lH,d), 3.91 (~H,s), 3.79 (3H,s) i 
EIMS, m/e 252 (M+). 
c H 
Percent Calculated 80.97 6.40 
Percent Found 81.40 6.64 
c[p-~-=·---=-c==--~----_::_=-:-_-::_=--_=::--=---~~=c- =· ~~-.--~~ -==~~~ =,--~~~'-'==--:~-------------·----· __ 
1,2,3,4-Tetrahydro-7-methoxy-1-phenyl-3-
napthalenone (2_) 
.61 
Compound~ (5 g, 0.02 mol) and trifluoracetic anhy-
dride (5.60 mL, 0.04 mol) were refluxed under nitrogen in 
100 mL of dry acetonitrile for 3.5 h according to the 
method of Fine and Stern. 89 The progress of the reaction 
was monitored for formation of product by TLC, Rf (B) 0.65. 
The cooled reaction mixture was washed with 5% Na2co3 and 
volatiles were removed in vacuo to leave 4.9 g of a resi-
due. Repeated recrystallization from EtOH yielded 1.5 g 
(30%) of 9: IR and NMR are identical to those reported 
for 9 in this section. 
METHOD A 
Cis- and Trans-6-Methoxy-3-(methylamino)-1-phenyl-1,2,3, 
4-tetrahydronapthalene Hydrochlorides (HC-10 and HT-10) 
Methylamine was passed into a stirred solution of 9 
(11.56 g, 0,046 mol) in 300 mL of methanol which was cooled 
in an ice bath as reported by Fries and Bertelli. 6 After 
3.54 g (0.114 mol) of methylamine had been bubbled in, 2 g of 
3A molecular sieves were added and the flask containing the 
solution was capped and allowed to stand overnight at 25°C. 
The resulting solution was filtered, theri concentrated in 
vacuo to a viscous oil. This oil was dissolved in 300 mL of 
methanol and cooled with stirring in an ice bath. To this 
----~--
solution was added 1 mg of bromcresol green and NaBH 3CN 
(2.8 g 1 0.045 mol). HCl gas t-Tas then passed into this 
62 
solution at such a rate as to just maintain a green-yellow 
color. When the solution turned yellow and"this color 
persisted (about 3 h) 1 the reaction mixture ~as poured 
into 500 g of ice and then basified to pH 10 with 50% 
aqueous NaOH~ The solution was then extracted with CH2c1 2 
(4 x 100 mL). The combined CH2c1 2 layers were dried 
(MgS04 ) 1 filtered and evaporated in vacuo to a dark green 
viscous oil. The oil was dissolved in ether and was pre-
cipitated as its HCl salt using ethereal HCl. The slightly 
off-white precipitate was filtered and redissolved 
~in .:.MeOH. ( 5 mL) . This solution was then filtered through 
a layer of charcoal on.a short silica gel column and eluted 
with additional portions of MeOH> ... After: removing 
volatiles under vacuum, this hydrochloride salt (6.9 g 1 
59.7%) was dissolved in CHC1 3 . Upon standing (24 h) 1 a 
white solid crystallized, and was collected by filtration 
and dried to give 4.1. g (35%) of the cis isomer HC-~.HC1 1 
mp 240-241°C. A second crop of solid was obtained 
from the filtrate. Two recrystallizations (CHC1 3/ether) 
of this crop provided 0.47 g (4%) of the mostly pure 
0 (<2% of cis by TLC) trans isomer HT-!Q.HC1 1 mp 226-228 C. 
The purity was indicated by TLC 1 Rfs (D) 0.43 (trans) and 
0.37 (cis). 
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Figu1·e XXI. NHR spectra of cis-7-methoxy-3-(methylamino)-1-phenyl-
1,2,3,4-tetrahydronapthalene hydrochloride [IIC-10 in Heon-d 4 1 0'\ w 
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Figure XXII. IR spectra of cis-7-methoxy-3-(methylamino)-1-phenyl-1,2,3,4-tetrahydronapthalene hydrochloride [BC-10). O'l 
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Figure XXIII. EH1S of 9_i~-7-methoxy-;3- (methylamine) -1-phenyl-1 1 2 1 3 1 4-
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Figure XXIV. NMR spectra of trans-7-methoxy-3-(methylamino)-1-phenyl-1,2,3,4-tetrahydronapthalene hydrochloride [HT-10 in MeOH-d 4 1. 0'\ 0'\ 
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Figure XXVI. CIMS of trans-7-metlloxy-3-(methylamino)-l-phenyl-1,2,3,4-
tetrahydronapthalene hydrochloride (IIT-10]. 0'\ 
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Compound HC-!Q: IR (KBr) 3475, 3100-2300, 1594, 1500, 
-1 1 1470 1 1090, 760 1 700 em,; H NMR (MeOH-d4 ) 7.40-6.30 (8H 1 rn) 1 
2.82 (3His), 2.65 (2H 1 dd), 2.46 (lH 1 rn) 1 1.92 (lH 1 dd); 
EIMS, rn/e 267 (M+). 
Analytical data (c18H22NOC1) 
c H N 
Percent Calculated 71.14 7.31 4.61 
Percent Found 70.26 7.53 4.48 
Compound HT-10: IR (KBr) 3430 1 3060-2500 1 2415 1 1594, 
-1 1 1470, 1260 1 1090, 1040, 760, 700 ern ; H NMR (MeOH-d4 ) 
7.91-6.75 (8H,rn) 1 4.93 (1H 1 t), 4.19 (3H 1 S) 1 3.92 (lH,rn), 
3.47 (2H,d), 3.31 (NH,s), 3.19 (3H 1 s), 2.81 (2H 1 br t); 
CIMS (NH 3 ) 1 m/e 267 (M + -1) +: 
Analytical data (c18H22NOC1 
c H N 
Percent Calculated 71.14 7.31 4.61 
Percent Found 69.73 7.17 4.55 
METHOD B 
Cis-7-Methoxy-3-(dimethylamino)-1-phenyl-1 1 2 1 3,4-tetra-
hydronapthalene Hydrochloride [HC-11] 
Compound HC-10 (1 g 1 0.003 mol) was heated under reflux 
with 4.6 rnL of 37% aqueous formaldehyde and 15 mL of MeOH 
for 45 min according to the method of Cannon et a1. 90 After 
70 
the solution cooled, NaBH4 (0.19 g, 0.005 mol) was added 
in small portions, with stirring over 30 min. The reaction 
mixture was then evaporated under reduced pressure. The 
residue was taken up in 50 mL of water and the solution was 
brought to pH 10 with 50% NaOH. It was extracted with three 
80 mL portions of ether and the pooled ether extracts were 
dried (Mgso 4 ), filtered and treated with ethereal HCl. 
The resulting solid was recrystallized from dry EtOH to 
0 yield 0.7 g (83%) of the cis isomer HC-ll.HCl; mp 202-203 C; 
IR (KBr) 3440, 3030, 2960, 2840, 2750-2200, 1607, 1500, 
-1 1 1460, 1290, 1030, 695 em ; H 300 MHZ NMR (MeOH-d4 ) 7.40-
6.20 (8H,m), 4.25 (lH,dd), 3. 76 (lH,m), 3.57 (3H,s), 3.19 
(2H,m), 2.95 (6H,s), 2.49 (lH,m), 2.03 (lH,dd), CIMS (NH 3 ), 
m/ e 2 8 2 ( M ± 1 ) +: 
Analytical data (c19H24 NOC1 
c H N 
Percent Calculated 71.18 7.70 4.51 
Percent Found 70.84 7.65 4.46 
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Figure XXVII. NMR spectra of cis-7-methoxy-3-(dimethyJ.aminol-1-pllenyl-
1,2,3,4-tetrahydronapthalene hydrochloride (IIC-!l in Me0It-d 4 }. _, 1--' 
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IR spectra of cis-~-methoxy-3-(dimethylamino)-1-phenyl 
1,2,3,4-tetrahydronapthalene hydrochloride [IIC-11]. 
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Figure XXIX. CIMS of ci.s-7-methoxy-3-(dimethy1amino)-1-phenyl-1,2,3,4-
tetrahydronaptha1ene hydroch1or ide (HC-lJJ. 
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Trans-7-Methoxy-3-(dimethylamino)-1-phenyl ·1,2,3,4-tetra-
hydronapthalene Hydrochloride [HT-11] 
Following the same procedure employed for the prepara-
tion of HC-ll, but using compound HT-!Q (0.1 g, 0.0003 mol) 
as starting material gave 0.08 g (76%) of HT-11 (recrystal-
lized from dry EtOH/ether): mp 198-200°C; IR (KBr) 3425, 
-1 1 3030-2300, 1605, 1500, 1460, 1290, 700 ~r ; H NMR (MeOH-d4 ) 
+. CIMS (NH 3 ), m/e 282 (M +).). 
Analytical data (c19H24NOC1) 
c H N 
Percent Calculated 71.18 7.70 4.51 
Percent Found 71.25 7.65 4.39 
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Figure XXX. NMR spectra of !=ran~-7-methoxy-3-(dimethy1amino)-1-pheny1-1,2,3,4-tetrahydronaptha1ene hydrochloride lHT-11 in Acetone-d 6 . 
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Figure XXXI. IR spectra of tr~ns-7-methoxy-3-(dimethy1amino)-1-pheny1-1, 2, 3, 4-tetrahydr.onaptha1ene hydrochloride {HT-11 1. 
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METHOD C 
·cis-3-[(Cyclopropylmethyl)methylamino]-7-methoxy-1-phenyl-
1,2,3,4-tetrahydronapthalene Hydrochloride [HC-13] 
Cyclopropanecarboxylic acid chloride (0.63 g, 0.006 mol) 
in dry c 6H6 (5 mL) was slowly added at 5°C to a solution of 
HC-10 (1.29 g, 0.005 mol), pyridine (0.88 g, 0.011 mol) 
dissolved in dry c 6H6 (20 mL) in a modified method of Grif-
fith et a1. 91 The mixture was stirred at room temperature 
for 3 h whereupon pyridinium hydrochloride precipitated. 
The solution was extracted with 2 x 20 mL of 0.1 N HCl, 
followed by 5% NaHC0 3 , then water to neutral pH. The organic 
layer was dried (Na 2so4 ), filtered and the solvent removed 
in vacuo. TLC analysis (3% MeOH/ethyl acetate) showed this 
to be one spot. This material was used direct~y for addi-
tional chemical processing without further purification. 
To a stirred solution of 1M borane in tetrahydrofuran (13 mL, 
0.013 mol) and maintained under nitrogen was added cis-3-
(N-methyl-N-cyclopropanecarboxamido)-7-methoxy-1-phenyl-
1,2,3,4-tetrahydronapthalene (1.39 g, 0.004 mol) prepared 
above. The mixture was heated to reflux for 4 h. It was 
then cooled in an ice bath and carefully treated with 200 mL 
of 10% HCl and then refluxed for an additional 1 h. After 
the mixture cooled, the solvents were removed in vacuo and 
the residue was dissolved in a mixture of methanol/water 
(5:1) and extracted with CH 2c1 2 (2 x 100 mL). The aqueous 
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Figure XXXIII. NHR spectra of cis-3-((cyclopropylmethyl)-methylamino)-
7-methoxy-l-phenyl-1,2,3,4-tetrahydronapthalene 
hydrochloride [IIC-13 in MeOH-d 4 ). 
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Figure XXXIV. IR spectra of,cis-~-[(cyclopropylmethyl)-methylamino]-7-
methoxy-1-phenyl-1~2,3,4-tetrahydronapthalene hydro-
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phase was further concentrated under reduced pressure, then 
basified to pH 11 with 50% NaOH and extracted with ether 
(3 x 150 mL), and the ether extracts were dried (Mgso 4 ), 
filtered and dried in vacuo over a 16 h period to leave a 
dark green oil. This oil was redissolved in dry ether and 
the hydrochloride salt was precipitated using ethereal HCl. 
The light brown precipitate was filtered and dissolved 
in MeOH (1 mL). This solution was then filtered through 
a layer of charcoal. on a short silica gel column. After 
removing volatiles under vacuo, this hydrochloride salt was 
recrysta~lized from 2-propanol yielding 0.72 g (45%) of 
HC-!l.HCl; mp 185-186°C; IR (KBr) 3450, 3005, 2950, 2840, 
-1 1 2720-2200, 1615, 1500, 1470, 1250, 1060, 700 em ; H 300 
MHz NMR (MeOH-d4 ) 7.40-6.23. (8H,m), 4.34 (lH,dd), 3.90 
(lH,m), 3.88 (lH,s), 3 .. 58 (3H,s), 3.22 (3H,d), 3.21 (2H,m), 
2.97 (3H,s), 2.48 (lH,m)., 2.06 (lH,dd), 1.19 (lH,m) 0.82 
(2H,d), 0. 50 (2H,d); .CIMS (NH 3 ), m/e 322 (M. + 1) +: 
Analytical data (c22 H28NOC1) 
c H N 
Percent Calculated 73.32 7.90 4.01 
Percent Found 73.20 7.74 4.13 
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Figure XXXVI. NMR spectra of trans-3-((cyclopropylmethyl)methylarnino)-7-
methoxy-1-pllenyl-1,2,3,4-tetrahydronapthalene hydrochloride 
[IIT-!l in HeOB-d 4 J. 
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Figure XXXVIII. CIMS of trans-3-[(cyc1opropy1methy1)methy1amino]-7-methoxy-1-
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Figure XXXVII. IR spectra of tra~s-3-((cyclopropylmethyl)methylamino]-7-
methoxy-1-phenyl-1,2,3,4-tetrahydronapthalene hydro-
chloride [IIT-13).: 
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Trans-3-[(Cyclopropylmethyl)methylamino]-7-methoxy-1-phenyl-
1,2,3,4-tetrahydronapthalene Hydrochloride [HT-13]. 
Following the same procedure employed for the prepara-
tion of HC-13, but using HT-10 (0.2 g, 0.0007 mol) as 
starting material gave 0.096 g (40%) of HT-13.HC1 (recrystal-
lized from 2-propanol/ether): mp 178-180°C; IR (KBr) 3480, 
-1 1 3005-2200, 1610, 1500, 1480, 1250, 700 em ; H NMR (MeOH-d 4 ) 
7.37-6.62 (8H,m), 4.44 (lH.,m), 3.75 (3H,s), 3.30 (2H,d), 
2.85 (2H,d), 2.63 (lH,s), 2.57 (3H,s), 2.04 (2H,m), 1.59 
(lH,m), 1. 23 (2H,q), 0. 90 (2H,q); CIMS (NH 3 ), m/e 322 
+ .. · (M.+l). 
Analytical data (c 22 H28NOC1) 
c H N 
Percent Calculated 73.32 7.90 4.01 
Percent Found 73.27 7.98 3.97 
METHOD D 
Ether Cleavage Reactions 
Cis-7-Hydroxy-3-(dimethylamino)-1-phenyl-1,2,3,4-tetra-
hydronapthalene Hydrobromide [HC-12] 
The demethylation of HC-11 to HC-12 is typical. 
Compound HC-11 (0.2 g, 0.006 mol) was added to 5 mL of 
boiling 48% HBr and the solution refluxed under nitrogen 
for 3h according to a modified method of Rice. 92 The 
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solution was cooled and excess HBr and water were removed 
in vacuo that had a KOH trap in the vacuum line. The 
light brown residue was dissolved in 1 mL of MeOH and 
filtered through a layer of charcoal on a short silica gel 
co+umn. After removing volatiles under vacuum_, the hydro-
bromide salt was recrystallized from EtOH yielding 0.17 g 
(78%) of HC-~.HBr: mp 240-241°C; IR (KBr) 3660-2840, 
!------------------------------
-1 1 1620-1340, 1260, 1035, 670 em ; H NMR (MeOH-d 4 ) 7.81-
6.10 (8H,m), 4.31 (lH,dd), 3.81 (lH,m), 3.24 (2H,m), 
3.05 (6H,s), 2.49 (lH,m), 2.03 (lH,dd), CIMS (NH 3 ), m/e 268 
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Figure IXL. NMR spectra of cis-7-hydroxy-3-(dimetllylkmino)-1-phenyl-
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Figure XL. 
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IR spectra of cis-7-hydroxy-3-(dimethylamino)-1-phedyl-
1, 2 1 3 1 4 -te trahydronaptbalene hydrobr:omide [ llC-!21 , I 
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Figure XLI. 
i 
cnts of cis-7-hydroxy-3- {dimethy1amino) -1-pheniyl-1, 2, 3, 4-
tetrahydronapthalene hydrobromide (liC-12). 
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Cis-3-[(Cyclopropylmethyl)methylamino]-7-hydroxy-1-phenyl-
1,2,3,4-tetrahydronapthalene Hydrobromide [HC-14] 
Compound HC-~ (0.30 g, 0.0008 mol) was added to 6 mL 
of boiling 48% HBr to give 0.25 g (79%) of HC-14.HBr: mp 
285-287°C; IR (KBr) 3650-2850, 1620, 1460, 1380, 1150, 1110, 
-1 1 660 em ; H NMR 7.40-6.15 (8H,m), 4.8 (HOD,s), 4.23 (lH,bq), 
~-Ai-1-(-1-H-;-m)-;-3-·-3-0-(MeOH-,bs_)_;-3 . 15 __ _(2H,_d)_! __ 2_.1_6 __ _{_2H ,_t_L, 2___. • .__..0=1.__ _ 
(lH,s), 2.89 (3H,s), 1.60 (2H,dd), 1.20 (lH,m), 0.91 (4H,t). 
CIMS (NH 3 ) m/e 308 (M + 1)~ 
92 
Trans-3-[(Cyclopropylmethyl)methylamino]-7-hydroxy-1-phenyl-
1,2,3,4-tetrahydronapthalene Hydrobromide [HT-14] 
Compound HT-~ (0.05 g, 0.00014 mol) was added to 
3 mL of boiling 48% HBr to give 0.042 g (78%) of HT-14.HBr: 
mp 280-283°C IR (KBr) 3650-2850, 1625, 1460, 1390, 1155, 
-1 1 1110, 660,crn; HNMR8.70 (lH,s), 7.53-6.70 (8H,m), 5.10 
(2H,d), 1. 76 (lH,s), 2.41 (2H,t), 2.17 (3H,s), 1.85 (2H,dd), 
1.41 (lH,m), 1.16 (4H,t); CIMS (NH 3 ) m/e 308 (M + 1)+: 
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RESULTS AND DISCUSSION (CHEMISTRY) 
The previously unreported aminotetralins in this series 
were prepared by the general reaction sequence depicted in 
schemes I, II, III and IV. (pages 100, 105, 107 and 108 respectively). 
The key intermediate ~ as depicted in scheme I. was 
prepared initially in a rather poor yield (30%) from ~ by 
refluxing in trifluoracetic anhydride [(CF 3Co) 2o]. Earlier 
attempts to cyclize ~ to 9 using trifluoromethanesulfonic 
acid at 59°C resulted in a dark brown product which was 
difficult to purify. 
In an attempt to increase the yield of ~' a sequence 
involving extensive modification of a Pummerer rearrange-
ment of a beta-keto sulfoxide, as described by Oikawa and 
Yonemitsu, 93 was used (scheme I). Ethyl 3-(3-methoxyphenyl) 
propenoate 3b is readily obtained in quantitative yield by 
esterification of 3-methoxycinnamic acid 3a. 
Conjugate addition of diphenyl copper magnesium bromide 
[generated from phenylmagnesium bromide and copper (I) 
chloride] to 3b, in a modified method of Suzuki et al., 86 
gave ethyl 3-phenyl-3-(3-methoxyphenyl)propanoate! in 70% 
yield. The beta-keto sulfoxide 5 was prepared from 4 and 
sodium methylsulfinylmethide in a very good yield. 
Trifluoroacetic anhydride catalyzed cyclization of 5 
gave 1,2,3,4-tetrahydro-7-methoxy-4-methylthio-1-phenyl-3-
99 
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napthalenone ~ as an oil in a 93% yield. 87 Cannon et al. 
recently cited the preparation of similarly substituted 
tetralones in which reductive desulfurization of the crude 
methyl sulfide compounds by catalytic hydrogenation was 
reported. 
An attempt was made in this research to purify and 
s-------isola±._e_c_o_mp_o_und_ 6 h:t__c_h_:r:-p_m_a togr_9.p_h_i!'lg ___ j_L(£..L on_ s_iJ_j__C(i_ 
gel followed by fractional crystallization from ethanol 
(See Experimental). Two products were obtained and labelled 
as 6A and 6B. These are labelled in accordance with the 
different NMR that was obtained for each of these. The 
IR and CIMS obtained are also reported in the Experimental 
section. The chemical nature of the actual intermediate 
here is in question, in view of the fact that NMR, IR and 
CIMS obtained do not seem to be consisten-t with the assigned 
structure. Crude compound 6 on the other hand is converted 
to 9 which has an assigned structure that is consistent 
with all of the spectral data and physical constants reported. 
A possible explanation is that compound ~ is unstable and 
decomposes when chromatographed. Some beta-tetralones have 
been reported as being unstable and better stored as their 
b~sulf~te salts. 87 F th k · · d · d t   ur er wor ~s requ~re ~n or er o 
establish the true nature of this intermediate. 
Crude compound ~ was converted to ~ by reductive 
desulfurization using aluminum amalgam [Al(Hg)]. 
Attempts to desulfurize ~ by catalytic hydrogenation or 
102 
refluxing in an ethanol solution combining nickel proved 
unsuccessful as indicated by recovery of mostly starting 
material. The NMR spectrum [Figure XVIII] of compound 2_ 
showed a triplet at 4.53 ppm for the C-1 benzilic protons, 
doublet at 3.08 ppm for C-2 methylene protons and a singlet 
at 3.60 ppm for the C-4 benzylic protons. The IR absorp-
tio_rls_[Figure XIX]_____9._l:'_~_co!'lsi_ptent for the structure indi-
cated showing most notably the C=O stretch at 1740 ern -1 
and chemical ionization mass spectra [Figure XX] showing 
rn/e 252 for the molecular ion is also as expected. 
The synthesis of racemic cis and trans compounds 10, 
designated as HC-10 and HT-10 respectively, was carried 
out in 60% yield by reductive arnination of compound 2_ 
----
using methylamine and NaBH 3CN [scheme II]. The isomers were 
separated by repeated fractional crystallization of the 
hydrochloride salts from chloroform. The marked preference 
( 9: 1) [Table I] for the formation of the cis isomer [HC-.~_Q) , 
. during NaBH 3CN reduction of the imine double bond of !Q, 
follows from the argument of steric approach control. Addi-
tion of hydrogen to the imine double bond from an approaching 
NaBH 3CN molecule occurs preferentially from the face of the 
molecule away from the hindering effect of the C-1 phenyl 
substituent. The IR spectra [Figures XXII and XXV) for both 
isomers of 10 are essentially similar and show major absorb-
ences at 3430-3475 crn-l for N-H stretch, at 3000-2300 crn-l 
for a broad aliphatic stretch, 3100 crn-l for aromatic C-H, 
"; 
., 
F=======-=---=-=~ ------~ -- ~------~ -------=====------=---
Table I 
Rlysical Data of the Cc:mpoon:is- .stmied 
~ field ~ 
Ccqn1ai n, Mi!tlxxi % np,OC Sol~ 
(±)ID-10.a:::J. Mi!O H MaHN A 35.5% 240-241 E 
( ±)ID'-10.a:::J. M:!O MaN H A 4% 226-228 F 
(±)ID-11.a:::J. M:!O H ~ B 83% 202-203 G 
(±)ID'-11.10. M:!O ~ H B~ 76% 198-200 H 
(±)ID-12.Eer HO H ~ D 78% 240-241 G {dec) 
(±)ID-13.IC. M:!O H ·~ c 45% 185-186 I 
(±)ID'-13.10. Mi!O ~ H c 40% 178-180 J 
(±)ID-14.Eer HO H ~ D 7gf, 285-287 G 
(±)Hr-14.HBr- HO ~ H D 78% 280-283 G 
~tal11zation Solvents: E, CB::l3, F, ClC.iEtber, G, E'ltH, H, E'ltWEther, 
I, 2-Propaml, J, 2-Propawl./Ether. 
bsee EXper:fm:!ntal Section. 
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-1 -1 1610 em for out of plane ring C=C bend and 750 em for 
=C-H bend. The CIMS for HT-10 is consistent showing a 
molecular ion peak, which also turns out to be the base peak 
at m/e 268 [Figure XXVI]. EIMS for HC-~ shows m/e 267 for 
its molecular ion but the base peak is at m/e 236 and is con-
sistent with the fragment [M - ·CH 3NH]+ [Figure XXIII]. 
NMR analysis for the rest of the compounds synthe-
sized in this study is discussed in more detail as a group 
of either cis or trans isomers in the section under a sub-
title NMR and stereochemical analysis. 
The amines HC-!l and HT-~ were prepared by acylating 
the corresponding cis isomer (HC-~) or the trans isomer 
(HT-10) respectively, followed by direct reduction of the 
amide with BH 3/THF [scheme II]. The IR spectra [Figures 
XXXIV and XXXVII] for HT- and HC-13 are nearly identical. 
Major absorptions are observed for N-H stretch peaking at 
-1 -1 3450-3460 em , broad aliphatic C-H stretch at 3005-2200 em 
-1 
aromatic C=C out of plane bend at 1610 em , c-c stretch for 
-1 -1 
cyclopropane ring at 1470 em and =C-H bend at 700 em 
CIMS [Figure XXXV] for HC-~ is as expected for the assigned 
structure showing a molecular ion peak at m/e 322 which is 
also the base peak. Other major peaks of interest are m/e 
"+ 206 [M - NHCH 3 , - CH 2Cyclopropyl, - CH 30] • CIMS [Figure 
XXXVIII] for HT-13 with molecular ion at m/e 322 shows an 
identical pattern. 
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The dirnethylarninotetrahydronapthalenes in this series 
designated as the cis (HC-11) and trans (HT-11) isomers 
were prepared by further N-rnethylating the corresponding 
cis (HC-!_Q_) and trans (HT-10) isomers respectively. In 
this reaction [scheme III] HC-!Q or HT-10 were methylated 
using 37% aqueous formaldehyde and NaBH 4 according to the 
;------me±ho_d_of_C_annon_e_t_a_l_.~_'I'hese are obtained from their 
---
corresponding starting material in fairly good yields 
[Table I]. TheIR spectra [Figures XXVIII and XXXI] for 
each compound again are nearly identical. The NH stretch 
-1 
absorption appears at 3440 ern , aromatic CH stretch at 
l -1 3030 ern- , broad CH stretch (aliphatic) at 2960-2200 ern 
and C=C stretch at 1607. CIMS [Figure XXIX] for HC-11 is 
consistent with rn/e 282 for the molecular ion. CIMS 
[Figure XXXII] for HT-11 shows a fragment (which is also 
the base peak) at rn/e 237 which is consistent with the ion 
[l·f-: N (CH3) 2·t. Since the N-alkylation or N-acylation and 
further reductions of the arnides formed from either HC-10 
or HT-10 were carried out at remote centers and do.not 
affect the isomer relationship each product was assumed to 
have the same cis or trans isomer relationship as their 
starting precursors. 
The methyl ether groups were cleaved by refluxing them 
in 48% HBr under nitrogen for three hours to give the free 
phenolic system for pharmacological testing. Earlier 
attempts at 0-dernethylation of HC-11 using lM BBr 3 in 
~-------~Svn thesis (Cont.) 
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dichloromethane yielded mostly inorganic salts and 15% 
of HC-12. The broad OH stretch for HC-12 [Figure IXL] is 
centered at approximately 3450 cm-l Other major absorb-
ences are reported in the Experimental section. 
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The cyclopropyl c-c stretch for HC-14 and HT-14 (which 
are the 0-demethylated products from HC-13 and HT-13 respec-
tively) 1 appears at 1470 cm-l [Figures XLIII and XLVI]. 
-----
The other major absorbences are the broad OH stretch cen-
-1 -1 tered at 3380 em 1 aromatic C-H stretch at 3040 em 1 C=C 
' 
-1 -1 
ring stretch at 1565 1 1460 em 1 C-N stretch at 1035 em 
-1 
out of plane OH bend at 670 em Other absorbences are 
indicated in more detail in the Experimental section. CIMS 
for HC-14 [Figure XLIV] shows m/e 308 for the molecular ion 
which is consistent for the assigned structure. Other peaks. 
of interest are those at m/e 252 [M - CH 2cyclopropyl]+. and 
m/e 222 [M- N(CH 3 )CH 2cyclopropyl]. CIMS [Figure XLVII] for 
HT-!! shows a base peak at m/e 252 which is consistent for 
the fragment [M - CH 2cyclopropyl]+ .. 
NMR AND STEREOCHEMICAL ANALYSIS 
The 1H chemical shifts and 1H- 1H coupling constants 
for the protons in the nonaromatic portion of the cis 
isomers of aminotetralin hydrochlorides in this study are 
reported in Table II and can be used to estimate the geom-
chosen here for discussion as it is typical for the cis 
compounds and also is one that shows minimal overlap of 
peaks. 
As a starting point, one can analyze the spectral por-
tions [Figure XXVII] due to the methine proton on C-3 and 
the methylene protons on C-4. The resonance signals due 
to the methine proton on C-3 are analyzed as the B portion 
of a AA' B CC' system. Signals due to the geminal protons 
on C-2 were sufficiently separated to allow their analysis 
as the CC' portion of a BCC'D system for each cis isomer 
reported. Initial parameter estimates were obtained by 
94 1 1 
standard methods with the aid of H- H spin decoupling 
when necessary. 
The JAB and JA'B for C-4 methylene protons in HC-11 
as indicated in Table II are 12.30 and 3.36 Hz respectively. 
These have like signs and are positive since vicinal coup-
lings in substituted ethanes have the same sign and are 
d d . t. 94 f d f . 1 d . regar e as posl lVe. Pre erre con ormatlona rawlngs 
110 
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and Newman projection [Figure XLVIII] show that proton A 
on C-4 being pseudoaxial to.proton Bon C-3 should exhibit 
the larger coupling constant. These C-4 methylene protons 
A and A' couple to produce JAA' of approximately -15.59 Hz 
and a multiplicity of doublet of doublets. JAA, and JCC' 
[Figure XLVIII and Table II] are assumed to be negative 
since geminal proton coupl_i-!:1~ __ j__~ _ _E~~1:._iv~_f_9E___TI\~~-~~H 2 ______ _ 
groups. These protons exhibit geminal coupling (with large 
coupling constants) since they are adjacent to an asymmetric 
center. There is also restricted rotation in the molecule 
such that each geminal methylene proton on either C-4 or 
C-2 can never be.placed in an identical environment to that 
previously experienced by the other and vice versa. Pro-
ton A on C-4 of HC-11 [Table II and Figure XXVII] for example 
does not couple equally as A' to proton B or any other proton 
in the spin system. 
More direct information on the ring conformation is 
obtained from the C-1 proton signal. Proton D on C-1 is 
unsymmetrically disposed with respect to protons C and C' on 
C-2 (Figure XLVIII). It resonates at 4.25 ppm with a 
multiplicity of double doublet (Table II). 
The coupling constants JCD and JC'D between protons 
on C-1 and the neighboring geminal protons on C-2 are 10.50 
and 5.58 Hz respectively. The geminal protons on C-2 are 
indicated as JCC' with coupling constant of approximately 
-15.50 Hz and are adjacent to two asymmetric centers. The 
-
s 
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Table II 
Chemical M.llti-
sbift, ppn plicity 
A 3.16 dd 
A' 3.24 dd 
~B 3.76 m 
ID-.11 c 2.03 dd 
C' 2.50 dd 
D 4.25 dd 
~ 2.95 db 
<Xll:3 3.57. s 
Ac 3.21 l:uDp 
A'c 3.21 mnp 
B 3.90 m 
m-.ue c 2.06 dd 
C' 2.48 Wmp 
D 4.24 dd 
d 
~ 
3.58 s 
a MEXH-d4 solutia:ls, values in ppn fran ~Si. 
Cnlpl1rg 
Cocstant,Hz 
JAA•=-15.59,JAC=12.30 
JAtg:3.36 
Jcc•=-15.50,Jce=12.30 
Jc,g:3.30 
Jnc=10.50,Jnc•=5.58 
Jrx:,c:1o.so,Jnc'=5.50 
b Doublet integr-ates for s1x protoos ~ d.:i.netbylam:im grrup. 
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Cis 
c ~ to overlap with the uethylene protoos of cycl.opropy.llllathyl the protoos oo C-4 were oot 
a:oanabl.e to detailed analysis. 
d N-cyclopropy.lllethyl resonamea are reported in the expt. section. 
e ~tbyl resonarce appears at delta 2.82 ppn as a s:ingl.et. 
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Conformation of cis-Isomers 
Figure XLV'II;r: 
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cl-c2 and c3-c4 bonds. 
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aforementioned coupling constants are consistent with a 
pseudo Ha·x-Ha·x and pseudo H . -H relationship between C-1 
ax eq 
and C-2 protons. Examination of molecular models and 
drawing of the preferred conformation (Figure XLVIII) 
reveals that the angle defined by the phenyl and the hydro-
gen at C-1 essentially bisect the aromatic portion of the 
tetralin ring. In this conformation, the nitrogen at C-3 
is in nearly an equitorial conformation. This conformation 
is preferred because of the unfavorable 1,3-pseudodiaxial 
interaction which would occur between the C-1 phenyl and 
C-3 amino group if the amino group existed in an axial 
position. 
Protons C and C' also exhibit chemical shift differ-
ences of approximately 0.43 ppm or in other words are dia-
stereotopic. This is expected since these protons are not 
interchangeable by a symmetry operation. 
An NMR study reporting the chemical shift values for 
95 
cyclohexane has appeared. In that study a difference of 
0.5 ppm was reported between the resonance frequencies of 
the axial and equitorial protons that can be measured at 
low temperature where the rate of chair-chair interconver-
sion is slow on the NMR time scale. Using the same analogy, 
it can be inferred that proton C' of C-2 is in a more 
equatorial position as shown in Figure XLVIII and could be 
expected to be the more upfield resonance that appears at 
approximately 2.03 ppm (Figure XXVII). Other reasoning 
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for this chemical shift difference between proton C and C' 
could be the electrical field effect or dipole moments 
+ generated by the phenyl group on C-1 or the CH 3N HCH 3 group 
on C-3. These field effects lead to a change of the charge 
density at particular protons such that depending on the 
direction of the C-H bond relative to the field vector, the 
honding_elec_trons __ ar_e_shi_f_t_ed__j::.Q_VLaxgs_ prgtcm_ C:~- or_~wa_y from 
----
proton C. These would be either shielded or deshielded 
respectively. Coupling constants for the nonaromatic pro-
tons of a tetrahydronapthalene ring with non-alkyl substi-
96 tuents on either the ring or nitrogen have been reported, 
and do seem to support the conclusions made in this disser-
tation. 
Due to overlap of-signals, the. spectral portions 
corresponding to the protons on C-4 and methylene protons 
of N-cyclopropylmethyl substituent of HC-13 were not amenable 
to detailed analysis. The overlapping signals from these 
methylene groups occur at 3. 22 ppm (Figure XXXIII). The 
four methylene protons of the cyclopropyl ring for HC-13 
exhibit chemical shift differences and are the most upfield 
signals in the spectra. On the whole, there is a good 
correlation between the chemical shift values, the coupling 
constants, nitrogen substituent effects and the assigned 
conformation. 
If we now turn our attention to the trans isomers and 
using the spectrum of HT-13 as typical (Figure XXXVI), the 
benzilic proton of C-1 now resonates as a triplet at 4.7 ppm 
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with JDC of 10.00 Hz (Table III). This is consistent with 
coupling to two magnetically and chemically equivalent 
protons as depicted in Figure XLIX. Methylene protons on 
C-2 appear as multiplets centered at 2.04 ppm. The benzylic 
protons on C-4 appear as a doublet centered at 3.81 ppm with 
JAB of 8.11 Hz. In this case there appears to be no gemi-
nal coupling between two benzylic protons on C-4. The C-3 ;--------
tertiary nitrogen and the C-1 phenyl ring in this conforma-
tion are both placed pseudo-equatorial and anti to each 
other with respect to a flat tetralin ring and are therefore 
noninteracting. This spectra was run on a 200 MHz instru-
ment. Resonance signals for the N-cyclopropylmethyl protons 
appear at between 1. 0 .. ppm and 2. 0 ppm and are the most 
upfield signals (Figure XXXVI). 
The spectra of the 0-demethylated compounds differ 
from those of their precursors primarily by the lack of the 
OCH 3 peak and appearance of the phenolic hydroxyl absorption 
which resonates at approximately 8.00 ppm. 
The assigned stereochemistry is consistent with the 
probability that reduction of the imino species to form the 
HC-10 intermediate by NaBH 3 CN occurred predominantly from 
the least hindered side of the molecule which is the side 
opposite the phenyl group on C-1. The N-substituent by this 
route is placed cis to the C-1 phenyl ring. Attack of the 
hydride from the more hindered side of the ring would yield 
the trans isomer. As indicated previously in the Experimental 
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section, the reduction yielded a 9:1 mixture of the cis and 
trans isomers. Thus, the results reached by analysis of· 
the NMR spectra are consistent with results predicted 
from mechanistic chemistry. 
PHARMACOLOGY 
MATERIALS AND METHODS 
The following preliminary studies on these compounds 
have been performed by Fatima Matos in the pharmacology 
department of the University of the Pacific. All compounds 
550g) were housed for one week prior to use and allowed free 
access to food and water. After decapitation, the longi-
tudinal muscle of the ileum was removed, as described by 
. 64 83 Kosterlitz et al. and Suet al., from a 6 em segment 
that was situated 10-15 em proximal to the ileocaecal valve. 
The strip of longitudinal muscle with the myenteric plexus 
attached was mounted between two platinum electrodes in 
either a 5 or 10 mL isolated tissue bath (37° C) containing 
Krebs bicarbonate buffer with the following composition 
(millimolar): NaCl (118.40), KCl (4.75), cac1 2 (2.54), 
Mgso4 (1.20), KH 2Po4 (1.19), NaHco 3 (25.0), glucose (11.1) 
plus choline chloride (20 micromolar) and pyrilamine maleate 
(0.125 micromolar) and oxygenated with 95% o 2 and 5% co2 . 
The muscle strip was connected to a transducer (Grass 
FT.03) and the resting tension adjusted to lg. Isometric 
contractions could then be induced by maximal ele6tric 
field.stimulation (80-90 V; 0.1 Hz; 0.25 msec pulse 
duration) on a Grass S44 stimulator and polygraphically 
120 
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recorded (Grass Model 7B) . The preparation was allowed to 
equilibrate for approximately 1.3 h with washes every 5-
10 min. On attainment of equilibrium the compounds were 
added to the bath in microliter quantities as either the 
HCl or HBr salts and left in contact with the tissue until 
a maximal effect had been reached (approximately 3 minutes). 
The II single dose" mej:_hgg __ ()f __ K_()?"t~:t:"lit:Z_c3.llcl watt 7~-~as _ _l.l~d ___ _ 
to establish concentration-response curves. The potency of 
all compounds as agonists indicated by the magnitude of 
depressed electrically induced contractions was compared to 
either NM or ethylketocyclazocine (EKC). NM is used as a 
strong agonist for the mu receptor and EKC as a strong 
agonist for kappa receptor. In one set of antagonist exper-
iments, naloxone HCl (Nx) was incubated in the bath for 
3-5 min either prior to or after the addition of the com-
pound (agonist) to be tested. The other set of antagonist 
experiments involved HC-14 or HT-!! as possible antagonists 
with addition to the bath for 3-5 min either prior to or 
after the addition of NM (agonist). The interval between 
doses was 15-20 min for NM, 40-60 min for EKC and 35-50 min 
for cis and trans isomers HC- and HT-10-14. 
Linear regression analyses were performed on data for 
the dose response for each isomer on a Hewlett-Packard 
model 86B computer using the general statistics PAC program. 
The antagonist potencies of each compound were analyzed by 
the method of Kosterlitz and Watt. 77 pA2 and KB values were 
determined from the following equations: 
:;=:=============-:-~==-- ----------
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A'/A 
where 
A' = Concentration of agonist mixed with antagonist. 
A = Concentration of agonist in the absence of 
B = Concentration of antagonist that produced the 
decrease in agonist response. 
Standard errors were calculated according to method described 
by Tallarida et a1. 84 
Results and Discussion 
(Pharmacology) 
The concentration-response curves for the compounds 
studied are depicted as Figure LX and were sketched using 
the linear portion and least squares method. With regard 
to agonist activity each compound tested in this prepara-
tion showed some degree of inhibition of ileum contraction. 
The micromolar concentrations for 50% inhibition of maximum 
response (rc50 ) as calculated from the regression line 
equation is reported along with the slopes and number of 
runs for each compound in Table IV. 
Comparison of potencies relative to that of NM calcu-
lated as ratios of the rc 50 concentrations gave a range from 
1/60 for compound HC-10 to 1/10,000 for HT-14. These ratios 
were even less by a factor of 1/10 in going from a comparison 
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1£-12 
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Hl'-14 
}M 
EXC 
'l""c<ble Tl. 
Agonist Activities 
Agonist Activities of Newly Synthesized .Am:l..ootetralin Analc:gues 
00 the Electrically Stimllate:i Guinea-pig neun 
Lotgi.tl.xlinal. M.lscle 
Coooentraticn 
R1 ~ ~ tP ICsoc rd 
H M:lO 6.5 - 33.0 12 6.79 0.66 
H M:lO 16.0 - 65.9 9 73.88 0.61 
~ ~ 6.3 -125 8 7.15 0.56 
'""<< ~ 5.6 - 55.9 7 38.37 0.67 
~ CII 12.9 -1c.1 10 353.48 0.65 
......--<J C:"i 12.9 -103.0 11 472.06 0.45 
/"<t.l CII 12.9 -103.0 8 >1000 0.35 
0.08 - 1.3 130 0.117 0.72 
0.001- 0.25 65 0.015 0.71 
CMi.crcm:Ua.r ccmentrat:i.als. 
~ of ilea teste:i. 
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Slope 
38.03 
28.03 
18.00 
ZT.2 
37.91 
c.7 
6.1 
37.4 
40.0 
comentra.tioos for 50% :i.nh:ibition of maximin resp:>nse. 'Ihe ICso concen-
tratioos are calculate:i fran regres.sioo line equation for each ~. 
dcorrelaticn coefficient. 
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of NM to a comparison with EKC. Compound HC-~ was the most 
potent isomer tested as an agonist in this preparation, 
reaching a maximum inhibition of ileum contraction of 85% 
at a concentration range of 6.5-33.0 micromolar. This 
percent maximum inhibition obtained is comparable to that 
of NM. The concentration range for NM in eliciting this 
inhibition is at 0.08 to 1.3 micromolar. HC-10 is 10-11 
times as potent as its trans isomer, which is also capable 
of reaching maximum inhibition approaching 73%. Compound 
HC-10 also exhibited a fast onset of action and fairly long 
duration of action and generally required a much longer 
recovery interval (approximately 45 min) or wash period. 
This is indicative of a high affinity for the receptor. It 
may also be due to high solubility in lipid. 
Compound HC-11 is the cis-dimethyl product obtained 
from HC-10. Maximum inhibition of ileum contraction by 
HC-11 is approximately 95% that of HC-10. Compounds HC-10 
and HC-11 thus show agonist activities which approach that 
for a full agonist. The monomethylated HC-10, perhaps 
because of an additional hydrogen bonding interaction, 
shows slightly better potency and affinity for the receptor 
than HC-11 as indicated by the slope of its dose response 
curve. Compound HC-!l with its N-methyl-N-cyclopropylmethyl 
substituent was designed to show mixed agonist-antagonist 
activity. It does as expected show low agonist activity 
which is of the order of 1/5 that of HC-10 and about 1/300 
that of NM. Agonist activity for HC-12 is also weak as 
126 
indicated by its rc 50 value of 353 micromolar. Of the 
compounds shown in Figure.LX the least potent in this prepa-
ration were HC-14 and HT-14. HC-14 is a slightly better 
agonist (140 times) for the GPI preparation than HT-14. 
Maximum inhibition obtained for HC-14 was about 40% at 
103 micromolar and about 30% for HT-14 at the same dose 
level. Compounds HC-!! and HT-!! are the 0-demethylated 
products from their corresponding precursors HC-_!l and HT-13 
respectively, and as stated in the introduction to this 
dissertation, were expected to show an enhancement of both 
agonist and antagonist activities. The potency of HC-14 
is about 1/12 that of its methylated precursor HC-13. 
A decrease in agonist activity is also observed for HC-12 
which is the 0-demethylated.product from HC-11. Compounds 
HT-11 and HT-13 which are the corresponding dimethyl and 
cyclopropylmethyl products from HT-~ showed very little 
agonistn:· in the ileum preparation with only an average of 
8.57% decrease in contraction at as high a dose of 125 micro-
molar for HT-11 and 103 micromolar for HT-13. Therefore, 
they are not reported in Figure LX. Neither HT-11 nor HT-13 
at concentrations of 125 micromolar and 103 micromolar 
respectively antagonized the effects of NI-1 on the ileum. 
pA;values for naloxone (Nx) antagonist of the agonists 
* Negative log of the antagonist concentration, which neces-
sitates doubling the concentration of the agonist in order 
to achieve the same level of response. 
;:,==============""===~-=-~--~·~-==-=~- -------~---~-
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HC-10, HT-10, HC-11 and HC-!l are reported in Table v. 
Competitive antagonism (parallel shift of dose response 
curve to the right) was demonstrated only in the case of Nx 
antagonism of compound HC-lQ. These were tested at a Nx 
dose of 0.704 micromolar except for HC-11 which was tested 
against a Nx dose of 0.176 micromolar. Nx with a pA2 value 
of 6.38 ± 0.20 reverses the agonist action of HC-10. Com-
pounds HT-10 and HC-1l with mean Nx pA2 values of 6.32 ± 
0.19 and 6.10 ± 0.024 respectively are also reversed but 
not completely by Nx and could be assumed to be showing 
activity which is opioid.in nature. Alternately, one might 
conclude that since the pA2 values are low and different 
from that for Nx antagonism of morphine, these compounds 
are also interacting with.nonopioid receptors which are not 
antagonized by Nx (Nx pA2 value against morphine is 8.50 
97 0.061 and against nalorphine is 7.99 ± 0.1~}. 
The greater potencies consistently demonstrated for 
the cis isomers .HC-10, HC-11, HC-13 and HC-14 versus those 
for HT-10, HT-11, HT-13 and HT-!! indicates that interaction 
of the drug with the receptor elements favors the molecular 
arrangement possessed by the. cis isomer. In other words, 
the pharmacophoric conformation required for binding to 
the receptor must be such that it favors the spatial arrange-
ment of the binding groups in the cis compounds, when these 
molecules align with the corresponding binding sites on the 
receptor. These conclusions for the agonist experiment are 
... 
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Table V 
Antagonist Activities of 
Aminotetralin Analogues 
Calculated pA2 Values for Naloxone (Nx) Antagonism of 
EC-~, E'l'-~, HC-~ and EC-~ and for BC-~, E'l'-~ 
Antagonism of Either NM or EKC on the Guinea Pig 
Ileum Longitudinal Muscle 
Concen-
Antagonist trationa Agonist 
NX 0.70 BC-10 
NX 0.70 H'l'-10 
NX 0.18 HC-11 
NX 0.70 BC-13 
NX 0.70 NM 
HC-14 25.80 NM 
ET-14 25.80 NM 
HC-14 25.80 EKC 
HT-1.1! 25.80 EKC 
aMicromolar concentrations. 
bstandard error of mean pA 2 values. 
cAntagonism by Nx is not competitive. 
N pA2 S.E.b 
7 6.38 0.20 
5 6.32c 0., 9 
4 5.59c 0 • .1!5 
4 6.o2c 0.2.1! 
8 8.46C 0. 11 
5 ~.96 0.28 
4 4.63 0. 13 
3 No 
Antagonism 
4 No 
Antagonism 
r=================::-:-: _______ -----
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. t t 'th th t d ' 1 b F ' 6 ' cons1s en Wl ose repor e prev1ous y y r1es 1n 
which compound 2C was shown to be a more potent agonist 
than 2T when tested in the mouse hot plate. 
The reduced agonist potencies in the GPI assay reported 
for compounds HC-!! and HT-14 are perhaps not unexpected 
for a mixed agonist-antagonist or partial agonist. Such 
mixed agonist-antagonist or partial agonist actions of these 
compounds could be revealed by determining their antagonist 
properties in the GPI assay against other known agonists 
such as NM or EKC. Such actions for HC-14 and HT-14 in the 
GPI assay are discussed later on in this section. 
There also is a loss of agonist activity upon intro-
ducing a phenolic hydroxyl demonstrated in going from com-
pound HC-11 to HC-12. This discrepancy was observed by 
Martinet a1. 27 in in vivo studies on other aminotetralins. 
This phenomenon is in marked contrast to the enhancement of 
agonist potency conferred by this group in morphine and 
. 98 99 
conformat1onally related structures. ' The phenolic OH 
is believed to effect this enhancement by functioning as a 
hydrogen bonding proton donor in the ligand-receptor associ-
ation process. This loss in agonist activity may be due to 
a number of factors. One might assume that the subsites 
responsible for the binding of norrnorphine and of either 
HC-!!, HT-14 or HC-12 in the GPI differ with respect to 
their recognition properties and locations on the receptor. 
This assumption is not supported by the fact that amino-
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tetralins are A,B-ring analogues of morphine and that a 
phenolic OH appears to be an absolute requirement for 
potent narcotic antagonistic activity. 100 However, the 
realization that the aminotetralins in this ser~es do pos-
sess a 1-phenyl substituent and the increased flexibility 
of the backbone of these molecules which may allow different 
receptor-interactions compared to the more rigidly struc-
tured normorphine, makes this assumption more feasible. The 
concept of multiple receptor binding modalities has been 
used to explain dissimilarities in binding of morphine and 
allylprodine. 12 The activities of these compounds is 
reasoned in terms of hydrophobic requirement of the P-
subsite which binds the phenyl of allylprodine and a T-
subsite which binds the phenyl ring of morphine (See Fig-
ure IV). The aforementioned assumption is an attempt to 
borrow from this analogy. For an interaction initiated by 
ion-pairing between the anionic receptor surface and the 
protonated amine on HC-14 for example, juxtaposing the 
tetralin ring with its phenolic group on the more hydro-
phobic P-subsite, may result in a detrimental effect in 
terms of potency because of the difference in specificity 
required by this subsite. On the other hand, binding of 
the 1-phenyl substituent of either HC-l! or HT-14 to the 
P-subsite would be a favorable association in terms of 
potency. 
A change in the ionic conductance of the muscle cells 
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in the presence of a charged compound is a phenomenon that 
may not be ruled out. A change in the ionic conductance of 
the muscle cells perhaps caused by HC- or HT-14 in a direc-
tion that inhibits release of Ca++ would result in less 
decrease in muscle contraction. 
Compounds HC-l! and HT-14 at a concentration of 25.75 
micromolar were evaluated for narcotic ant~gonis!~c ac_i:~"C~!L_ 
!~------------------
against either 0.156 or 0.314 micromolar NM and also against 
either 0.005 or 0.010 micromolar EKC. As antagonist on the 
GPI preparation, compounds HC-14 and HT-14 demonstrated 
weak activity for mu to none for kappa opioid receptors 
(Table V). The result, as indicated in terms of pA2 values 
of 4.96 for HC-14 and 4.63 for HT-14 when .NM was used as an 
agonist, and no antagonism when EKC was used as agonist, 
shows these to be somewhat better antagonists for mu than 
for kappa receptors. Compounds HC-~ through HC-13 and 
HT-10 through HT-13 showed no discernible antagonism of NM 
induced decrease in contraction in the guinea pig ileum 
preparation. These compounds, on the other hand, augmented 
to different degrees, the decrease in contractions induced 
by NM. 
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CONCLUSION 
Cis and trans isomers of a series of aminotetrahydro-
napthalenes have been synthesized. The cis intermediate 
(HC-!Q) was separated from the trans isomer (HT~lO) by 
fractional recrystallization and obtained predominantly 
Analysis of proton NMR spectral data (using proton 
ratios, multiplicity, chemical shift values, coupling con-
stants, and decoupling techniques) has been done and used 
in conjunction with other spectral and physical data to 
support the assigned stereochemistry. These data support 
the fact that both the phenyl group at C-1 and nitrogen 
substituents at C-3 of the tetralin ring are placed pseudo-
equatorially in the preferred conformation for the cis 
isomers. In the trans counterparts, both these groups are 
also located pseudoequatorially on the tetralin ring. The 
assigned stereochemistry is consistent with the probability 
that reduction of the imino species to form the HC-10 inter-
mediate by NaBH 3CN occurred predominantly from the least 
hindered side of the molecule which is the side opposite the 
phenyl group on C-1. Thus,the results reached by analysis 
of the NMR spectra are consistent with results predicted 
from mechanistic chemistry. 
Preliminary testing done on the GPI longitudinal muscle 
preparation show that compounds HC-10 and HC-11 have agonist 
~=-=======-=-==--=-----__ -_--_----=~.::=.~-::~- -------- -:-:=~~===~=--=-:-- ------=-::=-===~=-------
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activity approaching that for a full agonist but at a higher 
dose level than for NM. To attain the full agonist activity 
these compounds require 60 times the dose of NM. Alkyla-
tion of the secondary. amine (HC-!Q) to give the tertiary 
amine (HC-11) does not yield a more potent compound as 
indicated by the nearly identical rc 50 values for HC-10 and 
HC-11. 
--------
Compounds HC-13 and HT-10 showed weak agonist activity 
compared to HC-10 and HC-11. These compounds are not able 
to fully inhibit the GPI contractions. The weak potency of 
HC-11_ (approximately 1/5 that of HC-10) is consistent with 
a structure that replaces the hydrogen in HC-10 with a 
cyclopropylmethyl group (a substituent which generally 
imparts narcotic antagonistic activity in rigid structured 
opioids, e.g.,·morphine, or may result in agonist or inactive 
compounds in the non-rigid structured opioids, e.g., meperi-
dine) . 2 The fact that the Nx antagonism of compounds HC-13 
and HT-10 was also weak (pA2 approximately 6) is consistent 
with these compounds being partial agonist. 
Reduction in potencies for the phenolic compounds 
(HC-12, HC-14, HT-14) could be related to unfavorable inter-
action at the P-subsite postulated by Portoghese. 12 Agonist 
activity in these isomers resides predominantly in the cis 
conformation as revealed by the superior potencies of HC-!Q, 
HC-11, HC-!l and HC-14 over their trans counterparts. This 
observation is in agreement with that reported earlier 6 for 
jj===========:::-::------- ---=:::::::-_::_------~==---- ----- ----==-==--~~~-==-~--=~-- -- - -- ----------
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the nonphenolic congeners 2C and 2T. The nature of the 
interaction of the molecule with the receptor in eliciting 
this agonist activity must be such that it affords a better 
fit of the cis compounds to the receptor. 
pA2 values obtained for Nx antagonism of these com-
pounds show that they are not acting as classical opioid 
agonist in this GPI assay. Antagonism of NM activity by 
---------- -
HC-14 and HT-14 with pA2 values of 4.9 and 4.63 respectively 
show that these are acting at the mu receptor but also that 
their activity or affinity is weak at this receptor. Com-
pounds HC-l! and HT-14 do not antagonize EKC, hence they 
show no kappa antagonist activity. 
The diastereomeric aminotetrahydronapthalenes prepared 
in this research have been tested as racemic mixtures. It 
is possible that the weak agonist and/or antagonist activi-
ties of these congeners is the result of antagonism of the 
activity of the active enantiomer by its mirror image form 
at the receptor. In other words, better activity might be 
observed from the resolved enantiomers. Efforts at making 
these resolved forms are somewhat hampered by the lengthy 
number of steps required to get end products, unstable nature 
of some of the intermediates and tedious methods required in 
cleaning up the products. 
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